Top

Jack A. Roth, M.D., F.A.C.S.

Department of Thoracic and Cardiovascular Surgery, Division of Surgery

Present Title & Affiliation

Primary Appointment

Chief, Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor (Joint appointment), Department of Cardiothoracic and Vascular Surgery, The University of Texas Medical School at Houston, Houston, TX

Endowed Distinguished Chair Bud S. Johnson Distinguished Clinical Chair Emeritus, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Cardiothoracic and Vascular Surgery, The University of Texas Medical School at Houston, Houston, TX

Bud S. Johnson Distinguished Clinical Chair Emeritus, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1971	Johns Hopkins University School of Medicine, Baltimore, Maryland, US, MD
1967	Cornell University, Ithaca, New York, US, Economics, BA

Postgraduate Training

1999-2000	Executive Excellence Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
1992-1993	Executive Development Program, Rice University, Houston, Texas
1985-1986	unknown, Center for Advanced Training in Cell and Molecular Biology, Washington
1979-1980	Chief Resident, Division of General Surgery, UCLA School of Medicine, Los Angeles, California
1978-1979	Chief Resident, Division of Thoracic Surgery, UCLA School of Medicine, Los Angeles, California
1977-1978	Clinical Residency, Division of Thoracic Surgery, UCLA School of Medicine, Los Angeles, California
1975-1977	Clinical Residency, General Surgery, UCLA School of Medicine, Los Angeles, California
1973-1975	Research Fellowship, Division of Surgical Oncology, UCLA Center for the Health Sciences, Los Angeles, California
1972-1973	Clinical Residency, Surgery, Johns Hopkins Hospital, Baltimore, Maryland
1971-1972	Clinical Internship, Surgery, Johns Hopkins Hospital, Baltimore, Maryland

Licenses & Certifications

1986	Texas State Board of Medical Examiners
1983	American Board of Thoracic Surgery
1981	American Board of Surgery
1973	California State Board of Medical Examiners
1971	Maryland State Board of Medical Examiners

Experience & Service

Faculty Academic Appointments

Clinical Assistant Professor, Department of Surgery, The Medical Center, Georgetown University, Washington, 1982 - 1986

Lecturer in Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 1980 - 1986

Senior Investigator, Department of Surgery Branch, National Cancer Institute, Bethesda, MD, 1980 - 1986

Administrative Appointments/Responsibilities

Chair, Surgery-Tissue Procurement Working Group, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2000

Lung Cancer Biomarker Chemoprevention Consortium, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998 - 1999

Director, W. M. Keck Center for Innovative Cancer Therapies, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998 - Present

Committee Member, Coming Together to Conquer Cancer, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997 - 1998

Chief, Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 1995 - Present

Deputy Head for Research, Department of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1987 - 1993

Department Chair, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1986 - 2007

Head, Department of Thoracic Oncology Section, National Institutes of Health, National Cancer Institute, Bethesda, MD, 1982 - 1986

Other Professional Positions

Member, Data Monitoring Committee (DMC) VA Cooperative Study, CSP #2005, “Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy (VALOR), Houston, TX, 2016 - Present

Co-Leader Lung Cancer Moon Shot, Office of Strategic Initiatives, The University of Texas MD Anderson, Houston, TX, 2012 - Present

Consultant, Chair Scientific Advisory Board, Geneprex, Austin, TX, 2011 - Present

Member, Scientific Advisory Council, Alliance for Cancer Gene Therapy (ACGT), Greenwich, CT, 2006 - 2020

Consultant, Neotropix Scientific and Clinical Advisory Board, Malvern, PA, 2005 - Present

Member, Virology and Gene Therapy Program, Graduate School of Biomedical Science, The University of Texas, Houston, TX, 1998 - 2015

Member, National Comprehensive Cancer Network Esophageal/Gastric Cancer Panel, Houston, TX, 1997 - 1997

Member, National Gene Vector Laboratory Steering Committee, Houston, TX, 1997 - 2008

Member, Scientific Advisory Board, Gene Therapy Program, University of Virginia, Charlottesville, VA, 1997 - Present

Member, Leadership Committee, 25th Reunion, Johns Hopkins School of Medicine, Baltimore, MD, 1997

Member, The March Research Task Force Coming Together to Conquer Cancer, Houston, TX, 1997

Consultant, Chair Scientific Advisory Board, Introgen Therapeutics, Houston, TX, 1996 - 2009

Consultant in Research, Graduate School of Arts and Sciences, George Washington University, Washington, 1986

Member, Search Committee, Chairman of Thoracic and Cardiovascular Surgery, The University of Texas-Houston Medical School, Houston, TX, 1986

Member, Scientific Advisory Board, Carver Genetic Physics Corp, Seattle, WA, 1984 - 1986

Captain, Medical Corps, United States Army Reserves, 1971 - 1978

Review Committee, Cancer Regional Studies, Unknown

Member, Internatiional Registry of Lung Metastases, Unknown

Extramural Institutional Committee Activities

Member, the Advisory Committee for the Institutional Pre-Recombinant Advisory Committee (Pre-RAC), The University of Texas MD Anderson Cancer Center, 2016 - Present

Member, Lung Cancer Moon Shot Re-Biopsy Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

Internal Advisory Board Member, Head and Neck SPORE External/Internal Advisory Board, The University of Texas MD Anderson Cancer Center, 2015 - Present

Member, Council Oversight Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present

Member, Division of Surgery Research Council, The University of Texas MD Anderson Cancer Center, 2009 - Present

Member, Radiation Safety Committee, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Technology Review Committee for Institutional Grants, The University of Texas MD Anderson Cancer Center, 2002 - 2007

Member, Clinical Faculty Review Committee (CFRC), The University of Texas MD Anderson Cancer Center, 2001 - 2002

Member, Oversight Committee of the Cancer Therapeutics Discovery Program and Pharmaceutical Development Center, The University of Texas MD Anderson Cancer Center, 2001 - 2002

Member, Search Committee, Head, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 2001

Member, Research Council Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2006

Member, Clinical Translational Research Center (CTRC) Oversight Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2001

Chair, Division of Surgery Research Space Task Force, The University of Texas MD Anderson Cancer Center, 1999

Member, Committee to Define the Tumor Institute, The University of Texas MD Anderson Cancer Center, 1998

Co-Leader, Cancer Center Support Grant (CCSG): Lung Cancer Program, The University of Texas MD Anderson Cancer Center, 1998 - 2019

Member, Search Committee, Chairman, Department of Biochemistry and Molecular Biology, The University of Texas MD Anderson Cancer Center, 1997

Co-Chair, Search Committee, Division of Surgery, The University of Texas MD Anderson Cancer Center, 1997

Member, Search Committee Head, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, 1997

Member, Multidisciplinary Committee, The University of Texas MD Anderson Cancer Center, 1997

Member, Tissue Bank Committee, The University of Texas MD Anderson Cancer Center, 1996 - Present

Member, Technology Development Board Bylaws, The University of Texas MD Anderson Cancer Center, 1996 - 2007

Member, Research Institutional Directions, Small Working Group, The University of Texas MD Anderson Cancer Center, 1995

Member, Search Committee, Division Administrator, Division of Surgery and Anesthesiology, The University of Texas MD Anderson Cancer Center, 1994

Member, Division of Surgery Promotions Committee, The University of Texas MD Anderson Cancer Center, 1993 - 1994

Member, Division of Medicine Advisory Committee for Division Head Search Committee, The University of Texas MD Anderson Cancer Center, 1993

Chair, Chairman Department of Surgical Oncology Search Committee, The University of Texas MD Anderson Cancer Center, 1993

Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 1992 - 2002

Member, Executive Committee of the Prevention Faculty, The University of Texas MD Anderson Cancer Center, 1992 - 1995

Member, Chairman of Plastic Surgery Search Committee, The University of Texas MD Anderson Cancer Center, 1992 - 1993

Member, Program Committee of the 1991 Basic Science Colloquium, The University of Texas MD Anderson Cancer Center, 1990 - 1991

Member, Advisory Panel to Executive Vice President for Administration and Finance Concerning Research Issues, The University of Texas MD Anderson Cancer Center, 1990 - 1996

Member, Operating Room Subcommittee, The University of Texas MD Anderson Cancer Center, 1990 - 2006

Member, Quality of Care Committee - Division of Surgery, The University of Texas MD Anderson Cancer Center, 1989 - Present

Member, Investigational Drugs Subcommittee/Executive Committee, The University of Texas MD Anderson Cancer Center, 1988 - 1989

Co-Chairman, M. D. Anderson Research Development Working Group, The University of Texas MD Anderson Cancer Center, 1988 - 1989

Member, Executive Committee of the Science Faculty, The University of Texas MD Anderson Cancer Center, 1988 - 2000

Member, Smoking Cessation Committee, The University of Texas MD Anderson Cancer Center, 1988 - 1989

Member, Immunobiology Task Force - Division of Surgery, The University of Texas MD Anderson Cancer Center, 1988

Chairman, Division of Surgery Promotions Committee, The University of Texas MD Anderson Cancer Center, 1987 - 1988

Member, Chairman of Clinical Immunology and Biological Therapy Search Committee, The University of Texas MD Anderson Cancer Center, 1986

Chairman, Surgical Laboratory Research Committee, The University of Texas MD Anderson Cancer Center, 1986 - 1993

Member, Division of Surgery Promotions Committee, The University of Texas MD Anderson Cancer Center, 1986 - 1989

Member, Quality Assurance Committee, The University of Texas MD Anderson Cancer Center, 1986 - 1990

Member, Chairman of Department of Gynecology Search Committee, The University of Texas MD Anderson Cancer Center, 1986

Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 1986 - 1990

Chairman, Task Force for Research Space, Division of Surgery, The University of Texas MD Anderson Cancer Center, 1986

Editorial Activities

Editorial Board, Cureus.com, 2012 - Present

Member, Texas Medical Branch UTMB 2010 National Student Research Forum (NSRF), 2010 - Present

Editorial Board, Chinese Journal of Cancer Research, 2010 - 2012

Editorial Board, American Journal of Translational Research, 2009 - Present

Editorial Board, Chinese Journal of Lung Cancer, 2009 - Present

Editorial Board, Lung Cancer: Targets and Therapy, 2009 - Present

Editorial Board, Gastrointestinal Cancer Research, 2006 - 2011

Editorial Board, Clinical Lung Cancer, 2005 - Present

Senior Editor, Cancer Biology and Therapy, 2002 - Present

Charter Member, inScight, Internet Daily Science News Service, 1999 - Present

Editor, Lung Cancer, 1997 - 2005

Editoral Board, International Journal of Molecular Medicine, 1996 - Present

Editorial Academy, International Journal of Oncology, 1996 - Present

Associate Editor, The Cancer Journal, 1995 - 2000

Editorial Board, Clinical Cancer Research, 1994 - 2006

Editorial Board, Journal of Molecular Medicine, 1994 - 2006

Editorial Board, Journal of Thoracic and Cardiovascular Surgery, 1994 - 2002

Editorial Board, Journal of the American College of Surgeons, 1993 - 1996

Associate Editor, Cancer Gene Therapy, 1993 - 2013

Guest Editor, Lung Cancer for Seminars in Thoracic and Cardiovascular Surgery, 1993

Editorial Board, Surgery, 1992 - 1998

Associate Editor, Annals of Surgical Oncology, 1992 - 1998

Supplemental Editorial Committee, Cancer Research, 1992

Editorial Board, Journal of Surgical Oncology, 1991 - 1998

Editorial Board, Journal of Surgical Research, 1991 - 2001

Editorial Board, Current Surgery, 1990 - Present

Editorial Board, Journal of Immunotherapy, 1989 - 1997

Editorial Board, Cancergram (CIDAC), 1986 - 1989

Editorial Board, Physicians Data Query (PDQ), Cancer Treatment Information, 1985 - Present

Honors & Awards

2019	SPORE Leadership Award, National Cancer Institute
2019	President’s Faculty Excellence Award in Research, UT MD Anderson Cancer Center
2018 - 2024	Jack A. Roth Lectureship, Department of Thoracic and Cardiovascular Surgery, UT MD Anderson Cancer Cente
2017 - 2024	Jack A. Roth Fellowship in Thoracic Surgical Oncology, American Association for Thoracic Surgery Foundation
2015	Top Cancer Doctor, Newsweek / Castle Connolly
2015	Honorary Member, American Society for Radiation Oncology (ASTRO)
2015	Top Cancer Doctor, Newsweek (in conjunction with Castle Connolly)
2013 - 2024	Southeastern Texas' Top Doctors, American Registry, LLC
2011	Award for High Scoring Paper at 2011 Annual Meeting, American Association for Cancer Research
2008	America's Top Surgeons
2008	Elkin Distinguished Investigators Cancer Lectureship, Emory University School of Medicine Winship Cancer Institute, Atlanta, GA
2008	The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research, The University of Texas M. D. Anderson Cancer Center
2007	Fellow, American Association for the Advancement of Science
2007	O. T. Clagett Visiting Professorship, Mayo Clinic. Rochester, MN
2006	USPTO Records - "Top Patenters" in the life sciences, above the 99th percentile of the patent count distribution
2006	Recognized by peers as one of the top clinicians in the Houston area
2006	SPAR Award, Top 1% of cited authors for journals in Biology and Biochemistry
2005 - 2024	America's Top Doctors for Cancer, Castle Connolly Medical Ltd
2005 - 2024	America's Top Doctors, Castle Connolly
2004	Inaugural Glick Lecturer, Johns Hopkins School of Medicine
2003	Best Doctors 10 Year Veteran
2002	The Surgery Chief Resident Teaching Award, The University of Texas - Houston Medical School, Department of Surgery
2001 - 2003	Best Doctors, U.S. News & World Report
2000	Elaine & Gerald Schuster Distinguished Visiting Lecturer, Boston, MA, Dana-Farber Cancer Institute, Harvard Medical School
1998	Top 20 Texans, Texas Monthly Magazine
1997	Charles Moetel Lectureship, Mayo Clinic
1997	Gordon Hamilton-Fairley Lecture Award, British Association for Cancer Research and British Society for Surgical Oncology
1996	Inaugural Wittcoff Lecturer, Mayo Clinic
1996	Jack Sadler Memorial Lectureship, University of Colorado Health Sciences Center
1995	Charles L. Roper Visiting Professor, Washington University School of Medicine
1995	Elected Corresponding Member, European Society of Thoracic Surgeons
1995	Victor and Sigried Gilbertson Visiting Lecturer, University of MN, School of Medicine
1994	E.J. Tabah Visiting Professor in Surgical Oncology, Royal Victoria Hospital and McGill
1994	Ernest Bruell Lectureship, Cleveland Clinic Foundation
1994	The Award of Excellence for a Special Lecture, The 32nd Annual Congress of Japan Society for Cancer Therapy
1993	W.B. Cosbie Lecture, The Royal College of Physicians and Surgeons of Canada
1992	First Invited Scientific Plenary Lecturer, Radiation Therapy Oncology Group
1992	Lucy Wortham James Basic Research Award, Society of Surgical Oncology
1991 - 1992	The Best Doctors in America
1991	Distinguished Lecturer, University of Medicine and Dentistry of New Jersey
1990	One of 400 Best Doctors in America
1985	Merit Award, Grant R01 CA45187, Division of Research Grants and Biologic Response, Modifiers Program, National Institutes of Health
1984 - 2024	Fellow, American College of Surgeons
1981	Special Achievement Award: Characterization of an immunoregulatory factor in extracts of lung carcinoma, U.S. Department of Health and Human Services
1980	Mead Johnson Excellence of Research Award, National Research Forum
1977	Society of Surgical Oncology Resident/Fellow Award: Effect of Adriamycin and High-Dose Methotrexate Chemotherapy on In vivo and In vitro Cell-Mediated Immunity in Cancer Patients
1973	Resident-Fellow Clinical Research Award paper: Isolation of Soluble Tumor-associated Antigen From Human Melanoma, James Ewing Society (Society of Surgical Oncology)
1971	Outstanding Student Research Presentation, Johns Hopkins Medical Society
1967	B.A. Magna Cum Laude with distinction in all subjects, Cornell University
1967	Phi Beta Kappa, Cornell University

Professional Memberships

American Society for Radiation Oncology (ASTRO)

2015 - Present

VA Lung Study Surgical Advisory Committee

2014 - Present

American Association for Thoracic Surgery

2012 - Present

Society for Leukocyte Biology

2012 - Present

Lung Cancer Research Foundation Medical Advisory Board

2011 - Present

Radiation Safety Committee (RSC)

2011 - Present

American Association for Cancer Research

2007

American Radium Society

2007 - 2009

American Association of Academic Surgeons

2007 - Present

American Association for Thoracic Surgery

2004 - Present

International Association for the Study of Lung Cancer

2004 - Present

The Thoracic Surgery Foundation

2004 - Present

American Association for the Advancement of Science

2003 - 2006

Texas Faculty Association

2002 - Present

American Society of Gene and Cell Therapy

1999 - Present

South Texas Chapter of the American College of Surgeons

1999 - Present

International Society for Diseases of the Esophagus

1993 - 2011

American College of Chest Physicians

1992 - Present

Society of Surgical Oncology

1990 - 1993

Surgical Biology Club II

1989 - Present

American Surgical Association

1989 - Present

American Society of Clinical Oncology

1989 - 1991

General Thoracic Surgery Club

1988 - Present

Houston Surgical Society

1988 - Present

Harris County Medical Society

1987 - Present

American Medical Association

1987 - 2002

Texas Medical Association

1987 - Present

American College of Surgeons

1985 - 1992

Society of University Surgeons

1984 - Present

Society of Thoracic Surgeons

1984 - Present

Association of Academic Surgeons

1982 - 1984

American Association of Immunologists

1981 - 2011

Longmire Surgical Society

1980 - Present

Selected Presentations & Talks

Local Presentations

2025. Overcoming Resistance. Invited. Distinguished Scientist Seminar. Houston, Texas, US.
2014. Co-Chair: Integration of Research Resources for Personalized Risk Prediction. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2008. Chair, "Advances in Oncology Institutional Grand Rounds". Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2008. Image-guided Stereotactic Body Radiation Therapy in Lung Cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2008. Protein Expression Patterns in Prediction and Prognosis. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2007. Brief Overview: Proposed trial of resection vs stereotactic radiotherapy for early stage lung cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2006. Esophagectomy: How much is enough?. Conference. Texas Heart Institute at St. Luke’s Hospital, Baylor College of Medicine. Houston, TX, US.
2006. Esophageal Cancer: Are we making progress?. Conference. Houston Surgical Society. Houston, TX, US.
2005. Multidisciplinary management of locally advanced non-small cell lung cancer. Conference. Texas Heart Institute at St. Luke’s Hospital, Baylor College of Medicine. Houston, TX, US.
2004. 45th Clinical Cancer Conference, Chaired Session and presented. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2002. Development and Application of Therapies in Genitourinary Malignancies. Conference. J.W. Marriott Hotel. Houston, TX, US.
2002. Drug Discovery and Clinical Evaluation in the 21st Century, Gene Therapy. Conference. J.W. Marriott Hotel. Houston, TX, US.
2001. Restoration of Tumor Suppressor Gene Function in Cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2001. 2000-2001 Educational Seminar Series. Conference. Marriott Hotel. Houston, TX, US.
2001. The Decade Ahead, Gene Therapy: Future Direction. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2000. Gene Therapy in Thoracic Tumors. Conference. Marriott Hotel. Houston, TX, US.
2000. Genetic revolution. Conference. Nassau Bay Hilton Hotel and Marina. Houston, TX, US.
2000. 42nd Annual Clinical Conference. Conference. Cancer Research at the Millennium 2000, Westin Galleria Hotel. Houston, TX, US.
1999. Genitourinary Oncology. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
1998. Restoration of gene function in cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
1996. Surgery for esophageal cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
1994. Gene replacement strategies for the prevention and therapy of lung cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
1993. Gene therapy. Conference. Technology Transfer Conference. Houston, TX, US.
1993. Spotlight on Texas companies. Conference. BioInternational '93 Conference and Exhibition. Houston, TX, US.
1992. Biologic therapy in lung cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
1992. Novel strategies for prevention, diagnosis, and treatment of lung cancer. Conference. The University of Texas Health Science Center at Houston, Surgery Grand Rounds. Houston, TX, US.
1991. Molecular approaches for the prevention and therapy of cancer: the lung cancer paradigm. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
1989. Molecular studies of lung cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
1989. Lung cancer and Esophageal cancer. Conference. M. D. Anderson Hospital and Tumor Institute. Houston, TX, US.
1988. Resection of pulmonary metastases. Conference. M. D. Anderson Hospital and Tumor Institute. Houston, TX, US.
1988. Carcinoma of the esophagus. Conference. M. D. Anderson Hospital and Tumor Institute. Houston, TX, US.
1987. Multidisciplinary approach to cancer of the esophagus. Conference. M. D. Anderson Hospital and Tumor Institute. Houston, TX, US.
1987. Basics of molecular biology. Conference. M. D. Anderson Hospital and Tumor Institute. Houston, TX, US.
1987. Tumor Biology, Oncogenes. Conference. Department of General Surgery, M. D. Anderson Hospital and Tumor Institute. Houston, TX, US.
1987. Treatment of esophageal cancer. Conference. UTMS. Houston, TX, US.
1986. Surgical approaches to the treatment of lung cancer. Conference. M. D. Anderson Hospital and Tumor Institute. Houston, TX, US.
1986. Thoracic Oncology. Conference. UTMS. Houston, TX, US.

Regional Presentations

2007. Systemic nanoparticle-mediated gene delivery for cancer therapy. Conference. 5th International Conference on Gene Therapy of Cancer. Dallas, TX, US.
2006. SBRT vs. surgery for stage I NSCLC: Proposal for a randomized clinical trial. Conference. SBRT Symposium. Dallas, TX, US.
1996. p53 gene therapy used in treating cancer. Conference. Texas Oncology. Dallas, TX, US.
1989. New Approaches to the biology and therapy of lung cancer. Conference. University of Texas Medical School. unknown, US.
1989. Application of basic science to the study of lung cancer. Conference. Seminar in Applied Oncology. unknown, US.
1988. Oncogenes and tumor antigens. Conference. M. D. Anderson Hospital and Tumor Institute. unknown, US.
1987. Summary of lung cancer research, Visiting Professor. Conference. Dr. Longmire. unknown, US.
1987. Surgical Therapy of pulmonary metastases. Conference. M. D. Anderson Hospital and Tumor Institute. unknown, US.
1986. Combined modality therapy for carcinoma of the esophagus. Conference. M. D. Anderson Hospital and Tumor Institute. unknown, US.

National Presentations

2018. Fus-1 nanoparticles. Invited. 18th Annual Targeted Therapies of Lung Cancer Meeting. Santa Monica, CA, US.
2017. Tumor suppressor TUSC2 immunogene therapy is synergistic with anti-PD1 in syngeneic mouse models of lung cancer. Conference. AACR 2017. Washington, DC, US.
2016. Chair: Clinical Development of Cell and Gene Therapy. Invited. Alliance for Cancer Gene Therapy (ACGT). New York, NY, US.
2014. Induction Chemoradiotherapy (Cisplatin+Vinorelbin+Concurrent Radiotherapy) and Surgical Resection for Non-Small Cell Lung Cancer with Chest Wall Invasion: Initial Results of Central Japan Lung Study Group Trial 0801 (CJLSG 0801), paper presented by Kawaguchi K. Discussion #58 by Roth JA. Invited. Society of Thoracic Surgeons. Orlando, FL, US.
2014. Synchronous Multiple Non-Small Cell Lung Cancers: Molecular Staging and Survival Outcomes, paper presented by Zhang Y. Discussion #59 by Roth JA. Invited. Society of Thoracic Surgeons. Orlando, FL, US.
2012. Thoracotomy With an Unstable Neck. Conference. Inaugural Global Conference on Perioperative Medicine: Care of the Elderly and the Cancer Patient. Houston, TX, US.
2012. Induction Therapy for Potentially Resectable Stage 3 A NSCLC. Invited. Post-Graduate Course of the American Radium Society. Las Vegas, TX, US.
2011. Session Chair: BAP-1 From Bench to Bedside. Invited. Translational Cancer Medicine Symposium. Honolulu, HI, US.
2011. Debater: Treatment for Patients with Stage I NSCLC and Poor Lung Funtion: SBRT vs Sublobectomy?. Invited. American Radium Society 93rd Annual Meeting. Palm Beach, FL, US.
2010. Discussant: MicroRNA Mir-146b Decreases Metastatic Potential of A549 Lung Cancer Cells. Conference. American College of Surgeons 96th Annual Clinical Congress. Washington, DC, US.
2009. Prognostic issues including lymph node sampling and vascular invasion in early stage NSCLC. Invited. IASLC. San Francisco, CA, US.
2009. Gene therapy for lung cancer. Invited. IASLC. San Francisco, CA, US.
2009. Tumor suppressor gene therap. Conference. American Society of Gene Therapy. San Diego, CA, US.
2009. Forum Session “Lung Cancer Screening Controversies: Does every CT-detected lung cancer need intervention; Speakers: David Jablons, Peter Bach and Denise R. Aberle. Invited. American Association for Cancer Research. Denver, CO, US.
2009. Nanoparticles for Systemic Gene Delivery. Invited. 9th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. Santa Monica, CA, US.
2009. Nanoparticles for Systemic Gene Delivery. Invited. 9th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. Santa Monica, CA, US.
2009. STARS: Randomized study of lobectomy vs cyberknife for operable lung cancer. Invited. CyberKnife Symposium. San Francisco, CA, US.
2009. Debate: Treatment for early stage non-small cell lung cancer (NSCLC). Pro A trial of stereotactic radiosurgery for stage I non-small cell lung cancer: The time is now. Invited. 45th Annual Meeting Society of Thoracic Surgeons. San Francisco, CA, US.
2009. Debate: Treatment for Early Stage Non-Small Cell Lung Cancer (NSCLC). Pro: “A Trial of Stereotactic Radiosurgery for Stage I Non-Small Cell Lung cancer: The time is now. Invited. Society of Thoracic Surgeons 45th Annual Meeting. San Francisco, CA, US.
2009. Gene Therapy in Esophageal and Gastric Cancer. Invited. 2009 Gastrointestinal Cancers Symposium. San Francisco, CA, US.
2008. Five Consecutive Cases of Pneumonectomy Resulting in Complications or Bad Outcomes" Moderator. Invited. Tri-State Consecutive Case Conference on Lung Disease. Ponte Verde, FL, US.
2008. Innovative Therapies for Lung Cancer. Invited. Tri-State Thoracic Society Meeting. Ponte Verde, FL, US.
2008. Cancer Gene Therapy Using Nanoparticle Vectors, Keynote Speaker. Invited. 2008 NCI/NSTI Cancer Nanotechnology Symposium. Boston, MA, US.
2008. "Stereotactic Radiosurgery - An Alternative to Surgery for Small Tumors", Session V "Evolving Concepts and Techniques". Speaker,. Invited. American Association of Thoracic Surgeons Graduate Course. San Diego, CA, US.
2008. "Lung Cancer". Panelist. Invited. American Radium Society General Session. Dana Point, CA, US.
2008. Personalized cancer treatment: progress and prospects. Keynote Speaker. Invited. 7th Annual CyberKnife User's Meeting. Scottsdale, AZ, US.
2007. Stereotactic Radiosurgery for the treatment of stage I non-small cell lung cancer in high-risk patients, paper presented by Pennathur A. Discussion by Roth JA. Invited. American Association for Thoracic Surgery. Washington, DC, US.
2005. The clinical trial data on adp53 gene therapy of cancer. Adp53 clinical trials. Invited. American Society of Gene Therapy. St. Louis, MO, US.
2005. Genetics of Lung Cancer. Invited. 33rd Annual American College of Surgeons. Hollywood, FL, US.
2005. Keynote Speaker: Cancer gene therapy with viral vectors and synthetic nanoscale particles. Conference. Hollings Cancer Center Spring Symposium on Translational Therapeutics. Charleston, SC, US.
2005. Therapeutic gene transfer for lung cancer. Invited. American Association for Cancer Research. San Diego, CA, US.
2005. Local and systemic gene replacement for cancer. Invited. 5th Annual Targeted Therapies for the Treatment of Lung Cancer. Steamboat Springs, CO, US.
2002. Evolving Treatment Outcomes of Resected Esophageal Cancer Over Three Decades for 951 Patients at a Single Institution. Invited. 122nd Annual Meeting of the American Surgical Association. Hot Springs, VA, US.
2002. p53 Tumor Therapy. Invited. 93rd Annual Meeting of the American Association for Cancer Research. San Francisco, CA, US.
2002. Cancer Gene Therapy. Invited. 93rd Annual Meeting of the American Association for Cancer Research. San Francisco, CA, US.
2001. Strategies for Tumor Suppressor Gene Replacement in Cancer. Invited. American Society of Gene Therapy. San Diego, CA, US.
2001. Gene Based Approaches to Cancer Treatment. Invited. William P. Longmire Symposium. Los Angeles, CA, US.
2000. Gene Therapy: An Update. Invited. Gastrointestinal Cancer Research Forum. Orlando, FL, US.
2000. Gene Therapy for Lung Cancer. Invited. University of San Francisco, Stanford Thoracic Oncology Conference. San Francisco, CA, US.
2000. Restoration of tumor suppressor gene function: p53 and beyond. Invited. p53 and beyond 2000 Keystone Symposia. Keystone, CO, US.
1999. Viral and non-viral vectors for tumor suppressor gene replacement. Invited. AACR-NCI-EORTC. Washington, US.
1999. Activation of apoptosis pathways in lung cancer. Invited. Lung Cancer Biology Workshop. Aspen, CO, US.
1999. Neo-adjuvant therapy. Invited. ASTRO School of Radiation Oncology. Washington, US.
1999. Gene replacement for cancer: local, systemic, and adjuvant strategies. Invited. The George Washington University Grand Rounds. Washington, US.
1999. p53 As a therapeutic gene for cancer. Invited. American Society of Gene Therapy Scientific Committee Program. Washington, US.
1999. Gene replacement for cancer therapy. Invited. American Association for Thoracic Surgery. New Orleans, LA, US.
1999. Tumor suppressor gene therapy of cancer. Invited. Society of Surgical Oncology, 52nd Annual Cancer Symposium. Orlando, FL, US.
1999. Gene replacement for cancer: local, systemic and adjuvant strategies. Invited. The Ray A. Barlow Scientific Symposium on Gene Therapy in Cancer, Louisiana State University Medical Center. Shreveport, LA, US.
1998. Genetics of lung cancer. Invited. Lung Cancer: A Revolution in Care, 1998-99 Workshop Tour, Alliance for Lung Cancer Advocacy, Support, and Education. Houston, TX, US.
1998. Combined modality approaches for surgically resectable non-small cell lung cancer. Invited. Lung Cancer 98: A Multidisciplinary Approach, Memorial Hospital. Jacksonville, FL, US.
1998. Gene therapy in radiation oncology. Invited. 2nd Symposium on Concomitant Chemoradiotherapy, Vanderbilt University. Nashville, TN, US.
1997. Gene replacement strategies for cancer. Invited. Second Annual UCLA Human Gene Medicine Symposium. Los Angeles, CA, US.
1997. Gene therapy for lung cancer. Invited. Harvard Medical School General Thoracic Surgery. Cambridge, MA, US.
1997. Gene replacement strategies for cancer. Invited. 5th Annual Radiation Workshop at Round Top Gene Therapy Program. Houston, TX, US.
1997. Tumor suppressor genes. Invited. American Radium Society Annual Meeting. New York, NY, US.
1997. Approaches to using genes as cancer therapies. Invited. American Association for Cancer Research, Sunrise Session. San Diego, CA, US.
1997. Restoration of gene function for cancer. Invited. Congressional Caucus, STS/AATS Committee. Washington, US.
1997. Restoration of p53 function using gene therapy. Invited. Cambridge Healthtech Institute’s Second Annual New Cancer Strategies: p53. Washington, US.
1997. Gene therapy innovations. Invited. RPR Gencell Development/Marketing Meeting. Boca Raton, FL, US.
1996. Regulatory issues in gene therapy. Invited. Human Protection Workshop. Houston, TX, US.
1996. Tumor suppressor gene replacement. Invited. American College of Surgeons. San Francisco, CA, US.
1996. Gene therapy and the new biology. Invited. Lung Cancer-From Primary Care to Future Care, Duke University. Durham, NC, US.
1996. Gene therapy for non-small cell lung cancer. Invited. Perspectives in Lung Cancer. Atlanta, GA, US.
1996. Gene replacement for cancer. Invited. Eleventh Aspen Cancer Conference Workshop: Mechanisms of Toxicity and Carcinogenesis. Aspen, CO, US.
1996. Gene replacement for cancer. Invited. Invited Symposia Speaker, New Cancer Strategies: p53 Diagnostics & Therapy. McLean, VA, US.
1995. Gene replacement for cancer. Invited. Novel Strategies Against Resistant Cancers: A Special Conference of the American Association for Cancer Research. Fort Myers, FL, US.
1995. Clinical trials of p53 gene replacement. Invited. RPR Gencell Network Meeting. San Juan, PR, US.
1995. Gene replacement strategies for prevention and treatment of aerodigestive tract cancers. Invited. Invited Symposia Speaker, American Society for Therapeutic Radiology and Oncology 37th Annual Meeting. Miami Beach, FL, US.
1995. Adenovirus-mediated gene therapy for malignant mesothelioma: a comparison of immunodeficient and immunocompetent tumor models. Invited. 115th Annual American Surgical Association. Chicago, IL, US.
1995. Molecular genetic differentiation between primary lung cancer and lung metastases of other tumors. Invited. 75th Annual Meeting of the American Association for Thoracic Surgery. Boston, MA, US.
1994. Gene replacement strategies for therapy and prevention of lung cancer. Invited. Ninth Aspen Cancer Conference Workshop: Mechanisms of Toxicity and Carcinogenesis. Aspen, CO, US.
1994. Adjuvant chemotherapy for stage IIIa and a selected subset of stage IIIb non-small cell lung cancer. Invited. American Society Clinical Oncology Annual Meeting. Dallas, TX, US.
1994. Adenovirus-mediated gene therapy for malignant mesothelioma: a comparison of immunodeficient and immunocompetent tumor models, Invited Discussant. Invited. American Surgical Association 115th Annual Meeting. Chicago, IL, US.
1994. Gene Replacement strategies for therapy and prevention of lung cancer, Invited Symposia Speaker. Invited. American Association Cancer Research. San Francisco, CA, US.
1994. Gene replacement strategies for the prevention and therapy of lung cancer. Invited. Texas Division ACS - Excalibur: Day of Science. Houston, TX, US.
1994. Modulation of oncogene of the tumor suppressor gene expression: an approach to the gene therapy of cancer. Invited. American Cancer Society. Orlando, FL, US.
1994. Resection of N2/N3 lung cancer, Invited Professor. Invited. Society Surgical Oncology Meet the Professor. Houston, TX, US.
1993. Surgery for abdominothoracic metastatic disease. Invited. General Panel Discussion at the American College of Surgeons. San Francisco, CA, US.
1993. Surgical and neoadjuvant approaches to locally advanced, potentially resectable non-small cell lung cancer. Invited. Recent Advances in the Management of Lung Cancer, The UT Southwestern Medical Center. Dallas, TX, US.
1993. Use of retroviral vectors for the delivery of antisense constructs. Invited. 84th Annual Meeting American Association for Cancer Research. Orlando, FL, US.
1993. Modulation of oncogene and tumor suppressor gene expression for prevention and therapy of lung cancer. Invited. 4th IASLC Lung Tumor Biology Workshop. Airlie, VA, US.
1993. Gene therapy for lung cancer. Invited. Cancer Progress Conference, sponsored by Communitech Market Intelligence. New York, NY, US.
1993. Surgical approach to esophageal cancer. Invited. Southwest Oncology Group/Japanese Clinical Trials Summit. Honolulu, HI, US.
1993. Pulmonary resection of metastatic hypernephroma. Invited. Society of Thoracic Surgeons. San Antonio, TX, US.
1992. Molecular biology of NSCLC. Invited. UCLA Educational Symposium. Los Angeles, CA, US.
1992. Molecular strategies for therapy and prevention of cancer. Invited. American Society for Clinical Oncology Educational Conference Early Detection of Cancer: Challenges for Molecular Biology. Washington, US.
1992. Application of molecular biology to the diagnosis, prognosis, and therapy of thoracic cancers. Invited. First Annual General Thoracic Biology Club. Los Angeles, CA, US.
1992. Molecular surgery for cancer. Invited. Society of Surgical Oncology. New York, NY, US.
1991. Molecular approach for the prevention and treatment of lung cancer. Invited. 57th Annual Scientific Assembly, American College of Chest Physicians. San Francisco, CA, US.
1991. Modulation of oncogene expression as a potential therapy for cancer, biomolecular recognition and targeting strategies in the prevention and treatment of disease. Invited. University of Virginia. Charlotte, VA, US.
1991. Approaches in treating early lung cancer. Investigational strategies for detection and intervention in early lung cancer. Invited. National Cancer Institute. Bethesda, MD, US.
1991. Surgical aspects of esophageal carcinoma. Invited. Second Alabama Cancer Congress. Birmingham, AL, US.
1990. Molecular biology of non-small cell lung cancer. Invited. The Department of Continuing Education in Health Sciences, UCLA Extension and the UCLA School of Medicine. Los Angeles, CA, US.
1990. Neoadjuvant therapy for non-small cell lung cancer. Invited. The M. D. Anderson Experience, The Department of Continuing Education in Health Sciences, UCLA Extension and the UCLA School of Medicine. Los Angeles, CA, US.
1990. What's new in surgical oncology?. Conference. American College of Surgeons. San Francisco, CA, US.
1989. Prognostic Indicators for Soft Tissue Sarcoma in Patients with Pulmonary Metastases. Invited. 75th Annual Clinical Congress, American College of Surgeons. Atlanta, GA, US.
1989. New Developments in the treatment of lung cancer. Invited. Texas Academy of Family Practice Medical Surgical Conference. McAllen, TX, US.
1989. Multidisciplinary therapy of esophageal cancer. Invited. 24th Annual Cancer Symposium of the Academy. Cincinnati, OH, US.
1988. Molecular genetics and biologic modifiers of lung cancer. Invited. American College of Surgeons, Cancer Symposium. Chicago, IL, US.
1988. Cancer-induced immunosuppression: implications for therapy. Invited. American College of Surgeons, Cancer Symposium. Chicago, IL, US.
1988. Surgery for metastatic disease to the lungs and mediastinum: indications and approaches. Invited. Society of Thoracic Surgeons. New Orleans, LA, US.
1988. Preoperative chemotherapy and radiation for stage III non-small cell lung cancer. Invited. Society of Thoracic Surgeons. New Orleans, LA, US.
1988. Multimodality Therapy of Esophageal Cancer, The Cardiovascular Patient: State of the Art and Current Antibiotic Management. Invited. 3rd Annual Symposium. Austin, TX, US.
1986. Clinical trials of chemotherapy as an adjuvant to surgery. Invited. Current Approaches for the Diagnosis and Treatment of Gastrointestinal Cancer, 13th Annual Clinical Conference. Houston, TX, US.
1985. Changing Concepts in cancer surgery: lung metastases, patient selection, operative approaches, and results. Invited. Post-Graduate Course of the American College of Surgeons. Chicago, IL, US.
1984. Multidisciplinary Approach to Esophageal Cancer. Invited. Post-Graduate Course of the 3rd Annual USUHS Cardiothoracic Surgery Symposium. Bethesda, MD, US.
1983. Adjuvant Chemotherapy and Radiation Therapy for Esophageal Carcinoma. Invited. Postgraduate Course of Southern Thoracic Surgical Association. Marco Island, FL, US.
1979. Factors influencing patency of saphenous vein grafts. Invited. Society of Thoracic Surgeons. Phoenix, AZ, US.
1970. Effects of external counter-pressure in the treatment of hemorrhagic shock. Invited. Johns Hopkins Medical Institutions. Baltimore, MD, US.

International Presentations

2018. G. Alexander Patterson Invited Lecture: Thoracic Surgery in the Expanding Oncologic Universe. Invited. AATS International Thoracic Surgical Oncology Summit 2018. New York, US.
2015. Debate: Optimal Approach for Stage I Patients: Surgery. Invited. 16th Annual International Lung Cancer Congress. Huntington Beach, US.
2013. Chair: Advanced Disease and Outcomes. Invited. 15th World Conference on Lung Cancer. Sydney, AU.
2013. Chair: Monday’s Highlights of the Day – Radiotherapy, Radiology and Surgery. Invited. 15th World Conference on Lung Cancer. Sydney, AU.
2011. Discussant: The effects of investing in thoracic surgery on lung cancer resection rates. Invited. 14th World Conference on Lung Cancer. Amsterdam, NL.
2011. Local Recurrence After Definitive Chemoradiation: Is Salvage Surgery Indicated?. Invited. 14th World Conference on Lung cancer. Amsterdam, NL.
2010. Targeting the lung cancer genome, Distinguished guest speaker. Invited. 6th Annual Chinese Conference on Oncology (CCO). Shanghai, CN.
2009. NSCLC - Early Stage. Invited. 13th World Conference on Lung Cancer. San Francisco, US.
2009. Gene Therapy Approaches. Invited. Joint Oncology Symposium Yeditepe University Hospital System – M. D. Anderson Cancer Center. Istanbul, TR.
2009. Toward Personalized Lung Cancer Therapy. Invited. Joint Oncology Symposium Yeditepe University Hospital System – M. D. Anderson Cancer Center. Istanbul, TR.
2007. International randomized study to compare Cyberknife Stereotactic Radiosurgery with surgical resection in stage I non-small cell lung cancer (Lung Cancer STARS Trial). Invited. Japan Multinational Trial Organization. Tokyo, JP.
2007. Highlight of the Day. Invited. 12th World Conference on Lung Cancer. Seoul.
2007. SBRT vs. Surgery for Stage I Non-Small Cell Lung Cancer. Invited. First international symposium on stereotactic body radiation therapy and stereotactic radiosurgery. Orlando, US.
2006. Strategies for reducing deaths from lung cancer. Invited. “Meet the expert” at the 47th Annual Mtg of the Japan Lung Cancer Society. Kyoto, JP.
2006. Targeting the lung cancer genome. Invited. 47th Annual Mtg of the Japan Lung Cancer Society. Kyoto, JP.
2006. Personalized therapies for cancer. Invited. OncoProteomics World Congress. San Francisco, US.
2005. p53 Gene Therapy - Concept to Clinic. Invited. International Society for Cell and Gene Therapy of Cancer. Shenzhen, CN.
2005. Targeted molecular therapy in lung cancer - the P53 paradigm. Invited. 8th Annual Thoracic Disease Update: 2005 Multidisciplinary Conference 6th International Lung Cancer Congress. Cambridge, US.
2005. Induction and adjuvant therapy for resectable lung cancer. Invited. 6th International Lung Cancer Congress. Kauai, US.
2004. Combined modality treatment for esophageal cancer. Invited. Pulmonary and Critical Care Medicine. Taiwan, CN.
2004. Targeting the genetic lesions of lung cancer. Invited. Pulmonary and Critical Care Medicine. Taiwan, CN.
2004. Gene Therapy and Cancer. Invited. The 5th Princess Chulabhorn International Science Congress. Bangkok, TH.
2004. Gene Therapy. Invited. Gene Therapy Series, Kyoto University. Kyoto, JP.
2004. Current Status of Targeted Therapies for Cancer. Invited. Okayama International Forum on Gene and Cell Therapy. Okayama, JP.
2003. Gene Therapy. Invited. 10th World Conference on Lung Cancer. Vancouver, CA.
2002. New Gene Targets for Cancer Therapy. Invited. 11th International Conference on Gene Therapy of Cancer. San Diego, US.
2001. Gene Therapy of Lung Cancer. Invited. 2nd International Lung Cancer Congress. Kauai, US.
2001. Status and Future of Cancer Gene Therapy. Invited. American Society of Clinical Oncology. San Francisco, US.
2000. Integration of Gene Replacement with Multimodality Cancer Treatment. Invited. 9th International Conference on Gene Therapy of Cancer. San Diego, US.
2000. Biology of Lung Cancer. Invited. Lung Cancer Investigators Meeting. Hakone, JP.
2000. Local and Systemic Pro-apoptotic Gene Replacement for Non-Small Cell Lung Cancer. Invited. IASLC 9th World Conference on Lung Cancer. Tokyo, JP.
2000. Gene Replacement for Cancer. Invited. The Nobel Conference, 2000. Stockholm, SE.
2000. Molecular Approach to Therapy and Prevention. Invited. International Conference on Basic and Clinical Aspects of Cell Cycle Control. Siena, IT.
2000. Critical Issues of Cell-Based Vaccines and their Clinical Translation. Invited. 2nd Annual Walker’s Cay Colloquium. Walker’s Cay Island, BS.
1999. Activation of apoptosis pathways in lung cancer. Invited. International Cancer Gene Therapy. London, GB.
1999. Molecular basis for therapy in non-small lung cancer. Invited. Canadian Association of Medical Oncologists. Toronto, CA.
1999. Molecular basis for therapy in non-small lung cancer. Invited. Canadian Association of Medical Oncologists. Toronto, CA.
1998. Gene replacement for cancer: local, systemic, and combined modality strategies. Invited. 7th International Conference on Gene Therapy of Cancer. San Diego, US.
1998. Local and systemic gene replacement for cancer: treating metastases at the source. Invited. 29th International Symposium of the Princess Takamatsu Cancer Research Fund. Tokyo, JP.
1998. New approaches in drug development. Invited. American Society of Clinical Oncology. Los Angeles, US.
1996. Viral-mediated p53 gene replacement: preclinical models and clinical trials. Invited. 5th International Conference on Gene Therapy of Cancer. San Diego, US.
1996. Gene replacement for cancer. Invited. Gene Therapy-Current Clinical Status. London, GB.
1996. Stage changes after induction therapy. Invited. International Workshop on Intrathoracic Staging, IASLC. London, GB.
1996. Gene replacement for cancer. Invited. 5th IASCL Lung Tumor Biology Workshop. Ermatingen, CH.
1996. Gene replacement for cancer. Invited. Sixth International Congress on Anti-Cancer Treatment. Paris, FR.
1996. Ki-ras and p53 as target for gene therapy. Invited. 22nd National Cancer Congress of the German Cancer. Berlin, DE.
1995. Gene replacement for cancer. Invited. Fourth International Conference on Gene Therapy of Cancer. San Diego, US.
1995. Molecular genetics and lung cancer, Invited Keynote Speaker. Invited. Lung Cancer: Strategies for the 21st Century, Biology, Prevention and Management, University of Toronto. Toronto, CA.
1995. Biology and management of stage I lung cancer, Invited Keynote Speaker. Invited. Lung Cancer: Strategies for the 21st Century, Biology, Prevention and Management. Toronto, CA.
1995. Mutation in the p53 tumor suppressor gene in Barrett’s esophagus is a marker for development of adenocarcinoma: results of an international multi-institutional prospective study. Invited. 75th Annual Meeting of the American Association for Thoracic Surgery. Boston, US.
1994. Targeting cancer genes. Invited. First International Conference on Gene Therapy and Vaccines to Cancer. Washington, US.
1994. Gene replacement strategies for therapy and prevention of lung cancer. Conference. 32nd Annual Congress of Japan Society of Cancer Therapy Meeting. Okayama, JP.
1994. The molecular biology of non-small cell lung cancer. Invited. Bristol-Myers Squibb Company. Colorado Springs, US.
1994. The biology of lung cancer. Invited. Bristol-Myers Squibb Company. Colorado Springs, US.
1993. Modulation of oncogene and tumor suppressor gene expression. Invited. Second International Conference on Gene Therapy of Cancer. San Diego, US.
1993. Molecular biological approaches to cancer prevention and treatment. Invited. Lecture Symposia Speaker, The Royal College of Physicians and Surgeons of Canada. Vancouver, CA.
1993. Is an initial multifocal or diffuse appearance characteristic of adenocarcinoma in CLE. Invited. Invited Symposia Speaker, 4th International Polydisciplinary Congress (O.E.S.O.). unknown, US.
1993. What's new in surgery. Invited. Invited Symposia Speaker, IASLC. Brussels, BE.
1993. New insights into selecting patients likely to benefit from resection of pulmonary metastases. Invited. Invited Symposia Speaker, IASLC. Genoa, IT.
1993. Molecular genetic strategies for the prevention and therapy of lung cancer. Invited. Invited Symposia Speaker, IASLC. Genoa, IT.
1992. Future directions in the biology and treatment of esophageal cancer. Invited. International Conference on Biology and Treatment of Gastrointestinal Malignancies. unknown, US.
1992. Future directions in the treatment of esophageal carcinoma. Invited. International Conference on the Biology and Treatment of the Gastrointestinal Cancer. Frankfurt, DE.
1991. Molecular and cellular biology of lung cancer. Invited. 9th International Congress of Radiology Research. Toronto, CA.
1990. Multidisciplinary therapy for esophageal cancer. Invited. 15th International Cancer Congress. Hamburg, DE.
1990. Surgery for Cancer of the Esophagus. Invited. Educational Symposium, American Society of Clinical Oncology. Washington, US.
1987. Prognostic Indicators for soft tissue sarcoma patients with pulmonary metastases. Invited. International Symposium on Sarcomas. Tarpon Springs, US.

Formal Peers

2016. Roundtable: Lung Cancer Therapeutics. Visiting. New York, NY, US.
2013. Panel Discussion: Imaging Reporter Gene Expression in vivo – Tools for Following Therapy and Trafficking from Mouse to Man. Invited. Houston, TX, US.
2010. Targeting the Cancer Genome. Visiting. Houston, TX, US.
2009. Personalized Therapy of Lung Cancer: Advances in Surgery, Stereotactic Radiosurgery, and Targeted Molecular Therapy. Invited. Houston, TX, US.
2008. Targeting the Cancer Genome. Visiting. Atlanta, GA, US.
2007. Gene Therapy of Lung Cancer. Visiting. Maui, HI, US.
2007. Lung cancer Therapy: Getting Personal. Visiting. Rochester, MN, US.
2006. N2 disease: consensus and controversies, Keynote Speaker. Visiting. Miami, FL, US.
2006. Stereotactic radiation versus surgery for stage I NSCLC. Visiting. Maui, HI, US.
2006. Adjuvant therapy for treatment of non small cell lung cancer. Visiting. Houston, TX, US.
2006. Targeting Cancer Genes. Invited. Los Angeles, CA, US.
2006. Esophageal cancer: are we making progress?. Invited. Los Angeles, CA, US.
2006. Esophageal Cancer: Are we making progress?. Visiting. Los Angeles, CA, US.
2005. Esophageal Carcinoma: Are we making progress?. Visiting. Baltimore, MD, US.
2005. Targeting Cancer Genes. Visiting. Hong Kong, CN.
2004. Targeting thoracic cancers. Visiting. Baltimore, MD, US.
2004. Gene Therapy for Cancer: Gene Therapy. Invited. Philadelphia, PA, US.
2000. Gene therapy for cancer: p53 and beyond. Invited. Philadelphia, PA, US.
2000. Gene replacement for cancer. Invited. College Station, TX, US.
1999. Gene replacement for cancer: local, systemic, and adjuvant strategies. Invited. Washington, US.
1997. Local and systemic strategies for gene replacement for cancer. Visiting. unknown, US.
1997. Molecular approaches for therapy of lung cancer, Invited Lecturer. Visiting. Cleveland, OH, US.
1997. Gene replacement for lung cancer. Visiting. Dublin, IE.
1997. Future clinical approaches in the management of NSCLC with gene therapy, Invited Lecturer O'Reilly Hall. Visiting. Dublin, IE.
1997. Mayo Clinic Charles Moetel Lectureship. Visiting. Rochester, MN, US.
1996. Approaches to gene replacement for cancer. Visiting. Scottsdale, AZ, US.
1996. Strategies for gene replacement in lung cancer, Visiting Professor. Visiting. New York, NY, US.
1996. Jack Sadler Memorial Lecture. Visiting. Denver, CO, US.
1995. Gene replacement for cancer, Grand Rounds. Invited. Aspen, CO, US.
1995. Gene replacement for cancer. Invited. Minneapolis, MN, US.
1995. Gene replacement for cancer. Invited. Collegeville, PA, US.
1994. New approaches to cancer treatment and prevention: the lung cancer model. Invited. Cleveland, OH, US.
1994. Novel strategies - the lung cancer model, the Ernest Bruell Lectureship. Visiting. Cleveland, OH, US.
1994. Gene Therapy for lung cancer. Invited. Rockville, MD, US.
1994. Gene replacement strategies for cancer prevention and therapy, Keynote Speaker. Visiting. Houston, TX, US.
1994. Gene replacement strategies for therapy and prevention of lung cancer. Invited. Aspen, CO, US.
1994. Biology of non-small cell lung cancer: applications for prevention and therapy. Invited. Colorado Springs, CO, US.
1994. Gene replacement strategies for therapy and prevention of lung cancer. Invited. San Francisco, CA, US.
1994. Gene replacement therapy for lung cancer. Invited. Paris, FR.
1994. Advances in the treatment of lung cancer, Visiting Professor. Visiting. Montreal, CA.
1994. Esophageal carcinoma, Visiting Professor. Visiting. Montreal, CA.
1994. Oncogenes - from lab to clinic. Invited. unknown, FL, US.
1994. Resection for N2/N3 lung cancer. Invited. Houston, TX, US.
1994. Gene therapy of cancer, Visiting Professor. Visiting. Montreal, CA.
1993. Molecular surgery for cancer, Distinguished Lecturer. Visiting. Newark, NY, US.
1993. Molecular strategies for the prevention and treatment of cancer. Visiting. New Orleans, LA, US.
1992. Recent studies in molecular biology of lung cancer. Invited. Los Angeles, CA, US.
1991. Molecular approaches to cancer therapy, Visiting Professor. Visiting. Los Angeles, CA, US.
1991. Multidisciplinary management of esophageal cancer, Visiting Professor. Visiting. Los Angeles, CA, US.
1990. New therapeutic approaches to lung cancer. Invited. San Diego, CA, US.
1990. Cancer update: lung cancer. Invited. Houston, TX, US.
1989. Tumor stasis factor. Invited. Alameda, CA, US.
1989. Training of thoracic surgical oncologists. Invited. Cincinnati, MD, US.
1989. The role of surgery in the management of pulmonary metastases. Invited. Cincinnati, OH, US.
1988. Optimizing management of primary bone tumors: resection of pulmonary metastases. Invited. Houston, TX, US.
1988. Multimodality therapy for esophageal cancer, surgery and survival for pulmonary metastasectomy, multimodality therapy for lung cancer. Invited. Toronto, CA.
1988. Surgical Resection of Pulmonary Metastases. Visiting. Toronto, CA.
1988. Multimodality therapy of esophageal cancer, Visiting Professor. Visiting. Milwaukee, WI, US.
1988. Tumor stasis factor. Invited. Alameda, CA, US.
1987. Therapy of esophageal cancer. Invited. Chicago, IL, US.
1987. Immunotoxin therapy of metastatic cancer. Invited. San Diego, CA, US.
1987. Oncogenes and tumor antigens. Invited. Del Mar, CA, US.
1986. Surgery for metastatic pulmonary nodules. Invited. Washington, US.
1985. Combined modality therapy for cancer of the esophagus. Invited. Washington, US.
1985. Multimodality therapy of esophageal carcinoma, Visiting Professor. Visiting. Baltimore, MD, US.
1985. Combined modalities for the treatment of epidermoid carcinoma of the esophagus, Visiting Professor. Visiting. Baltimore, MD, US.
1985. Surgical treatment of metastases in man. Invited. Houston, TX, US.
1985. Adjuvant therapy for epidermoid carcinoma of the esophagus. Invited. Washington, US.
1984. Canadian esophageal cancer study group. Invited. Quebec, CA.
1984. 3rd Annual Hilton Head. Invited. Hilton Head, SC, US.
1984. Resection of pulmonary metastases, Visiting Professor. Visiting. Washington, US.
1983. Multimodality therapy of esophageal carcinoma, Visiting Professor. Visiting. Baltimore, MD, US.
1982. Aggressive resection of pulmonary metastases from sarcomas, Visiting Professor. Visiting. Chapel Hill, NC, US.
1981. Surgery of lymphoma. Invited. Tampa, FL, US.

Less

Grant & Contract Support

Date:	2026 - 2029
Title:	Eliminating disease persistence in EGFR-mutated lung cancer
Funding Source:	LCRF/UCSF
Role:	Co-I
ID:	FP00028358

Date:	2025 - 2028
Title:	Therapeutic Potential of TTFields in Targeted Therapy-Induced Lung Cancer Persister Cells
Funding Source:	AACR/UCSF
Role:	Collaborator
ID:	FP00020559_Res1

Date:	2025 - 2027
Title:	Proteomics-driven precision molecular mapping of patient tumors to preclinical models in lung cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R21CA288901-01A1

Date:	2024 - 2029
Title:	Integrative Metabolomics-Driven Multi-Omics Analysis to Uncover Lung Cancer Vulnerabilities
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP00021745

Date:	2023 - 2026
Title:	The potential of TTFields treatment to target drug-tolerant persister cells in lung cancer
Funding Source:	AACR/UCSF
Role:	Collaborator
ID:	FP00020559

Date:	2023 - 2024
Title:	Imaging Metabolic Alterations Related to Treatment in Lung Cancer (Lai)
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	5U54CA224081-06

Date:	2023 - 2024
Title:	Metabolic targeting of platinum resistance in humanized models of head and neck cancer (Roth-Jeffrey Myers-Boyi Gan)
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	5U54CA224081-06

Date:	2023 - 2028
Title:	University of Texas PDX Development and Trial Center
Funding Source:	NIH/NCI
Role:	PD/PI (Contact)
ID:	2U54CA224065-05

Date:	2022 - 2027
Title:	BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP) - Project 2 & Administrative Core
Funding Source:	NIH/NCI/UCSF
Role:	Multi PI
ID:	U54CA224081

Date:	2022 - 2025
Title:	Restoration of REQORSA(TUSC2) and NPRL2 expression to resensitize NSCLC and SCLC to targeted and immune therapies
Funding Source:	Genprex, Inc
Role:	PI
ID:	RCTS 61014

Date:	2021 - 2025
Title:	SPORE: Targeting Lung Cancer Vulnerabilities
Funding Source:	NIH/NCI
Role:	Overall PI, Co-Director Administrative Core, Co-Director Career Development Program, Co-Director Development Research Program, Co-Investigator Project 2
ID:	2 P50 CA070907-21

Date:	2021 - 2023
Title:	W81XWH-20-LCRP-IITRA / DoD Lung Cancer, Investigator-Initiated Translational Research Award
Funding Source:	Department of Defense (DOD)
Role:	Other Significant Contributor
ID:	LC200049

Date:	2020 - 2025
Title:	Advanced mammalian models for identification of novel drug combinations effective for non small cell lung cancer
Funding Source:	NIH/NCI
Role:	Multi-PI
ID:	R01CA255117

Date:	2020 - 2025
Title:	Development of novel combination immunotherapy using patient derived xenografts in humanized mice
Funding Source:	NIH/NCI
Role:	Multi-PI
ID:	R01CA240431

Date:	2019 - 2021
Title:	Theranostic, Stroma, and Lung Cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Collaborator
ID:	LC180249

Date:	2019 - 2020
Title:	SPORE: Developing Personalized Medicine for Lung Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	P50CA070907-20S1

Date:	2019 - 2022
Title:	Bay Area Team Against Resistance: Overcoming Resistance to Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	4U54CA224065-02

Date:	2019 - 2021
Title:	Harnessing protein methylation signaling to lung cancer therapy
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Mentor
ID:	LC180702

Date:	2019 - 2020
Title:	University of Texas PDX Development and Trial Center: Using patient derived xenografts(PDXs) in humanized mice to model the human tumor immune microenvironment
Funding Source:	NIH/NCI
Role:	PI
ID:	3U54CA224065-03S

Date:	2019 - 2024
Title:	A Theranostic, Stroma Approach for Lung Cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1 R01 CA243499-01

Date:	2019 - 2024
Title:	Development of novel combination immunotherapy using patient derived xenografts in humanized mice
Funding Source:	NIH/NCI
Role:	Multi-Principal Investigator
ID:	GRANT12718888

Date:	2019 - 2022
Title:	Novel approaches for identifying tumor-reactive TILs and TCRs for personalized adoptive T cell therapies in NSCLC. - Project 3 - Novel approaches for identifying tumor-reactive TCRs and developing personalized adoptive T cell therapies (ACT)
Funding Source:	UTMDACC - CCSG
Role:	Co-PI

Date:	2019 - 2024
Title:	Develop novel precision therapies for non-small cell lung cancer with molecularly annotated patient-derived xenograft models
Funding Source:	NIH/NCI
Role:	Co-I
ID:	GRANT12629382

Date:	2018 - 2020
Title:	Activation of the Innate Immune Response to Enhance Nivolumab Combinatorial Efficacy Using Novel Humanized Kras-mutant Patient Derived Xenograft (hPDXs) Mouse Models
Funding Source:	MDACC - Emerson Collective
Role:	PI

Date:	2018 - 2019
Title:	Southwest Early Clinical Trials Consortium: Anticancer Activity of MDM2 inhibitor AMG232 in lung cancer PDXs
Funding Source:	NIH/NCI
Role:	Co-I
ID:	UM1CA186688-04

Date:	2018 - 2023
Title:	Role of SETD5 in chromatin regulation and tumorigenesis
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	FP00002191

Date:	2018 - 2022
Title:	Novel Therapeutic Approaches for the Treatment of Cancer Using TUSC2 and Immunotherapy
Funding Source:	Genprex, Inc
Role:	PI
ID:	13032845COR

Date:	2018 - 2019
Title:	Evaluation of Novel Combinatorial Therapies of Kras-Mutated Lung Tumors in Humanized Patient Derived Xenografts (hPDXs)
Funding Source:	MDACC - Petrin KRAS
Role:	PI

Date:	2018 - 2023
Title:	Introducing a theranostic reporter target for lung cancer
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	R01 CA201174 - Resubmission

Date:	2018 - 2020
Title:	Metabolic Reprograming by Immune Activation and Checkpoint Blockade Inhibition for Improving Immunotherapy in Lung Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R21CA226505-01

Date:	2018 - 2021
Title:	Using lung cancer PDX models to identify effective anti-KRAS therapeutic agents
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP180137 - IIRA

Date:	2017 - 2023
Title:	University of Texas PDX Development and Trial Center - Admin Core
Funding Source:	NIH/NCI
Role:	Co-Core Leader
ID:	1U54CA224065

Date:	2017 - 2019
Title:	University of Texas PDX Development and Trial Center: Cancer Center Support Grant – PDXNet Supplement
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	3U54CA224065-01S1

Date:	2017 - 2023
Title:	University of Texas PDX Development and Trial Center
Funding Source:	NIH/NCI
Role:	PI
ID:	1U54CA224065

Date:	2017 - 2023
Title:	University of Texas PDX Development and Trial Center - Pilot Core
Funding Source:	NIH/NCI
Role:	Core Leader
ID:	1U54CA224065

Date:	2017 - 2023
Title:	PDXNet: Project 1: PDX-based trials of precision medicine for treatment of KRAS mutant lung cancers
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1U54CA224065

Date:	2017 - 2022
Title:	Multidisciplinary Subspecialty Pathology Research Fellowship Program
Funding Source:	NIH/NCI
Role:	Preceptor

Date:	2017 - 2022
Title:	Therapeutic targeting of lung cancers with aberrant glutathione homeostasis
Funding Source:	NIH/NCI
Role:	Co-PI

Date:	2017 - 2020
Title:	Immunogene Therapy for Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	DP170013

Date:	2017 - 2018
Title:	Evaluation of immunogene therapy in Kras mutated humanized patient derived xenografts (PDX)
Funding Source:	Lung Cancer Moonshot - Petrin KRAS
Role:	PI

Date:	2016 - 2019
Title:	NCLC Patient-Derived Xenografts for Accelerating Development of Anti-Lung Cancer Drugs
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5P50CA070907-18S1

Date:	2016 - 2021
Title:	Circulating miRNA Biomarkers in Lung Cancer
Funding Source:	NIH/NCI
Role:	Co-PI

Date:	2016 - 2023
Title:	Integrative Risk Prediction Models across Cancer Continuum
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2016 - 2021
Title:	miRNA in Lung Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP160655

Date:	2015 - 2020
Title:	Repurposing Auranofin for Lung Cancer Therapy
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2015 - 2020
Title:	Introducing a theranostic reporter target for lung cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	R01 CA201174

Date:	2014 - 2019
Title:	UT SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	5P50 CA70907-20

Date:	2014 - 2020
Title:	Single Arm Study of Stereotactic Ablative Radiotherapy (SABR)
Funding Source:	Varian Medical Systems
Role:	PI

Date:	2014 - 2021
Title:	Epigenetic miRNA, SNP Signatures, and their Functions in Lung Cancer Outcomes
Funding Source:	NIH/NCI
Role:	Multi-Principal Investigator
ID:	5R01CA176568

Date:	2013 - 2016
Title:	Role of MicroRNA in Lung Cancer Risk & Clinical Outcome Prediction
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-Project Leader
ID:	RP130502

Date:	2013 - 2019
Title:	Cancer Center Support Grant Project 10: Lung Cancer
Funding Source:	NIH/NCI
Role:	Co-Program Leader
ID:	2 P30 CA016672-41

Date:	2013 - 2016
Title:	Cellular and Molecular Mechanisms of Gastrointestinal Cancers
Funding Source:	NIH/NCI
Role:	Significant Contributor
ID:	5P01CA130821

Date:	2010 - 2015
Title:	Genome-wide association study of clinical outcomes of non-small cell lung cancer
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2010 - 2011
Title:	Proteasome dysfunctional and chemoresistance in lung cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Other Significant Contributor

Date:	2010 - 2011
Title:	Nanoroses for Non-Invasive Imaging and Therapy of Lung Cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Other Significant Contributor

Date:	2010 - 2011
Title:	Role of RNA-binding protein, HuR in regulation of tumor growth and multiple pathways in lung cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Other Significant Contributor

Date:	2010 - 2015
Title:	TFAP2B as a novel tumor-selective biomarker and therapeutic target for lung cancer
Funding Source:	NIH/NCI
Role:	Collaborator

Date:	2010 - 2015
Title:	Synergism of nanoparticles with molecular ligands for cancer imaging and therapy
Funding Source:	NIH/NIBIB
Role:	Other Significant Contributor

Date:	2010 - 2014
Title:	Predicting response and overcoming resistance for targeted lung cancer therapy
Funding Source:	CPRIT
Role:	Co-I

Date:	2010 - 2014
Title:	TFAP2B as a Novel Tumor-selective Biomarker and Therapeutic Target for Lung Cancer
Funding Source:	CPRIT
Role:	Co-I

Date:	2010 - 2014
Title:	Nanoparticle-based imaging and therapy enablers for lung cancer
Funding Source:	CPRIT
Role:	Other Significant Contributor

Date:	2010 - 2014
Title:	Antitumor Activity of a Novel CTD Inhibitor NSC-743380 for Treatment of Lung Cancer
Funding Source:	CPRIT
Role:	Co-I

Date:	2009 - 2013
Title:	Phase I/II clinical trial combining FUS1-nanoparticles and erlotinib in stage IV lung cancer
Funding Source:	V Foundation
Role:	PI

Date:	2009 - 2011
Title:	Protein Fingerprints of Fresh Lung Cancer Tissues
Funding Source:	NIH/NCI
Role:	Consult

Date:	2009 - 2010
Title:	Targeted IMAT Multifunctional Nanoparticles for Bronchioaveolar Lung Cancer
Funding Source:	Joan's Legacy
Role:	Other Significant Contributor, Collaborator

Date:	2008 - 2014
Title:	UT SPORE In Lung Cancer - Project 5
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	5-P50-CA70907

Date:	2008 - 2014
Title:	UT SPORE in Lung Cancer
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	5-P50-CA70907

Date:	2008 - 2009
Title:	Nanoparticles for treatment of metastatic lung cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	CA114924

Date:	2008 - 2014
Title:	Cancer Center Support Grant Project 10: Lung Cancer
Funding Source:	NIH/NCI
Role:	Co-Program Leader
ID:	CA016672 33

Date:	2008 - 2012
Title:	Systemic non-viral gene therapy for cancer
Funding Source:	NIH/NCI
Role:	Consult
ID:	R01 CA113450

Date:	2008 - 2013
Title:	International Study of SBRT vs. Surgery
Funding Source:	Accuray, Inc
Role:	PI
ID:	CS2008-00022496DH

Date:	2008 - 2010
Title:	Nanoparticles for treatment of metastatic lung cancer
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	1-R43-CA114924

Date:	2008 - 2009
Title:	EGFR-targeted hybrid nanoparticles as therapy for lung cancer
Funding Source:	The University of Texas Lung SPORE
Role:	Collaborator

Date:	2007 - 2010
Title:	PKR mediated a chemo-and-radio resistance in cancer cells
Funding Source:	NIH/NCI
Role:	Consult
ID:	CA124388

Date:	2007 - 2009
Title:	Genome-wide analysis and identification of tumor-specific hTERT promoter-binding proteins as cancer biomarkers and therapeutic targets
Funding Source:	Kadoorie Charitable Foundation
Role:	Co-I

Date:	2007 - 2012
Title:	PROSPECT - Profiling of resistance patters & oncogenic signaling pathways in evaluation of cancers of the thorax and therapeutics target identification - Project 2: Tumor Molecular profiles in patients with operable non-small cell lung cancer (NSCLC); impact on stage, and relapse pattern
Funding Source:	Department of Defense (DOD)
Role:	Project Leader
ID:	W81XWH-07-1-0306

Date:	2007 - 2011
Title:	Tumor PTK-targeted therapy by FUS1 and PTK inhibitor
Funding Source:	NIH/NCI
Role:	Co-I
ID:	CA116322

Date:	2007 - 2012
Title:	PROSPECT - Profiling of resistance patterns and oncogenic signaling pathways in evaluation of cancers of the thorax and therapeutic target identification - Project 3: Molecular Profiling of Non-Small Cell Lung Cancer Tissue Specimens and Serum and Plasma Samples: Correlation with Patient Response and Tumor Resistance to Chemotherapy
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Project Leader

Date:	2007 - 2012
Title:	PROSPECT - Profiling of resistence pattersn & oncogenic signaling pathways in evaluation of cancers of the thorax and therapeutics target identification. Core A: Administrative Core
Funding Source:	Department of Defense (DOD)
Role:	Co-Director
ID:	W-1XWH-07-0306

Date:	2006 - 2007
Title:	Systemic non-viral gene therapy for cancer
Funding Source:	Charlotte Geyer Foundation
Role:	Consult

Date:	2006 - 2007
Title:	Phase I study of intravenous DOTAP:Cholesterol-fus1 nanoparticle complex (DOTAP:Chol-fus1) in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy
Funding Source:	Commonwealth Foundation for Cancer Research
Role:	Co-I

Date:	2005 - 2007
Title:	Functional characterization of kinase inhibitors, related pathways and activity in vivo
Funding Source:	Astrazeneca
Role:	PI

Date:	2004 - 2009
Title:	VITAL - Vanguard Trial Investigators of Therapeutic Approaches to Lung Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	W81XWH-04-1-0142

Date:	2004 - 2005
Title:	Translation of tumor suppressor genes into new therapeutics for lung cancer
Funding Source:	UTMDACC Polo on the Prairie
Role:	PI

Date:	2003
Title:	Helen Lho and Jin Roy Ryu Fund for Gene Therapy
Funding Source:	Pongsan America Corporation
Role:	PI

Date:	2003 - 2009
Title:	The University of Texas SPORE in Lung Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	CA70907

Date:	2003 - 2008
Title:	Cancer Center Support Grant - Project 10 - Gene Therapy and Molecular Therapeutics Program
Funding Source:	NIH/NCI
Role:	Program Director
ID:	CA16672

Date:	2003 - 2007
Title:	Expression of proapoptotic genes for cancer therapy
Funding Source:	NCI
Role:	Consult

Date:	2002 - 2006
Title:	The TARGET Lung Cancer Program - Project 9 -Use of perfluorocarbons to enhance pulmonary gene transfer
Funding Source:	U.S. Army (DOD)
Role:	Consult
ID:	DAMD17-02-1-0706

Date:	2002 - 2006
Title:	The TARGET Lung Cancer Program - Project 7 -Mechanisms and treatment application of tumor suppressor gene FUS1 in lung cancer
Funding Source:	U.S. Army (DOD)
Role:	Co-I
ID:	DAMD17-02-1-0706-03

Date:	2001 - 2006
Title:	IGFBP 6 - A target in lung cancer prevention
Funding Source:	NCI
Role:	Consult
ID:	CA091727

Date:	2001 - 2004
Title:	The BESCT Lung Cancer Program - Project 3 - Experimental molecular therapeutics approaches to lung cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	DAMD17-01-0689

Date:	2000 - 2005
Title:	Retinoid signaling in new lung cancer prevention models
Funding Source:	NCI
Role:	Collaborator
ID:	CA080686

Date:	1999 - 2005
Title:	Restoration of Apoptosis in Cancer
Funding Source:	NCI
Role:	PI
ID:	CA78778

Date:	1999 - 2004
Title:	Multidisciplinary Program for Human Cancer Gene Prevention Therapy
Funding Source:	W. M. Keck Foundation
Role:	PI

Date:	1999 - 1999
Title:	Development of Therapeutic Treatment and Prevention of Lung Cancer
Funding Source:	Introgen Therapeutics, Inc
Role:	PI

Date:	1998 - 1999
Title:	Genotype/Phenotype Biomarkers
Funding Source:	NIH/NCI
Role:	Co-I
ID:	CA68437

Date:	1998 - 2019
Title:	Cancer Center Support Grant Project 10: Lung Cancer
Funding Source:	NIH/NCI Bridge
Role:	Co-Program Leader
ID:	2 P30 CA016672-43

Date:	1998 - 1999
Title:	1998 Annual Symposium on Fundamental Cancer Research
Funding Source:	NCI
Role:	Co-Chair
ID:	CA78308

Date:	1998 - 2003
Title:	Cancer Center Support Grant - Project 10 - Gene Therapy and Molecular Therapeutics Program
Funding Source:	NIH/NCI
Role:	Program Director
ID:	CA016672

Date:	1996 - 2003
Title:	The University of Texas SPORE in Lung Cancer
Funding Source:	NCI
Role:	PI
ID:	CA070907

Date:	1996 - 2001
Title:	Developing Molecular Therapy in Head and Neck Cancer
Funding Source:	NCI
Role:	Collaborator
ID:	R29DE11689

Date:	1996 - 1999
Title:	Development of Therapeutic Treatment and Prevention of Lung Cancer, Amendment No. 3
Funding Source:	Introgen Therapeutics, Inc
Role:	PI

Date:	1995 - 1997
Title:	Clinical Protocol for Modification of Tumor Suppressor Gene Expression in Non-Small Cell Lung Cancer with a Retroviral Vector Expressing Wild-type (normal) p53, Amendment No. 3
Funding Source:	Introgen Therapeutics, Inc
Role:	PI

Date:	1995 - 1999
Title:	Targeted Gene Delivery for Lung Cancer Gene Therapy
Funding Source:	NCI
Role:	Consult
ID:	CA66037

Date:	1995 - 1996
Title:	Development of Therapeutic Treatment and Prevention of Lung Cancer
Funding Source:	Introgen Therapeutics, Inc
Role:	PI

Date:	1995 - 1995
Title:	Clinical Protocol for Modification of Tumor Suppressor Gene Expression in Non-Small Cell Lung Cancer with a Retroviral Vector Expressing Wild-type (normal) p53
Funding Source:	Introgen Therapeutics, Inc
Role:	PI

Date:	1993 - 1998
Title:	Biochemical Role of the p53 Gene Product in Human Cancer
Funding Source:	NCI
Role:	Consult
ID:	CA57403

Date:	1993
Title:	Gene Therapy of Lung Cancer
Funding Source:	Texas Biomedical Development Partners
Role:	PI

Date:	1992 - 1995
Title:	Modification of Oncogene Expression
Funding Source:	NCI
Role:	PI
ID:	CA45187

Date:	1992 - 1993
Title:	Lung Cancer Early Detection Working Group (LCEDWG)
Funding Source:	Johns Hopkins University
Role:	Co-I

Date:	1991 - 1995
Title:	Ecogenetics of Lung Cancer in Minority Populations
Funding Source:	NCI
Role:	Co-I
ID:	CA55769

Date:	1991 - 1993
Title:	Function of p53 Tumor Suppressor Gene Product
Funding Source:	Texas Higher Education Coordinating Board
Role:	Consult

Date:	1991 - 1996
Title:	Evaluation of Genetic Markers of Lung Cancer Development and Regulation of Their Expression
Funding Source:	The G. Harold and Leila Y. Mathers Charitable Foundation
Role:	PI

Date:	1991 - 1991
Title:	Development of New Therapies that Interfere with Cancer Cell Growth
Funding Source:	The Brown Foundation
Role:	PI

Date:	1990
Title:	Biology of & Novel Therapeutic Approaches for Epithelial Cancers of the Aerodigestive Tract
Funding Source:	The G. Harold and Leila Y. Mathers Charitable Foundation
Role:	Co-Chairmen for the Keystone Symposium

Date:	1988 - 1993
Title:	Training of Academic Thoracic Surgical Oncologists
Funding Source:	NCI
Role:	PI
ID:	CA09611

Date:	1987 - 1989
Title:	Purification and Characterization of Tumor Stasis Factor
Funding Source:	Triton Biosciences
Role:	PI

Date:	1987 - 1990
Title:	Protocols TSDM87-044 and TSDM87-045
Funding Source:	Bristol Myers
Role:	Co-Principal Investigators

Date:	1987 - 1992
Title:	Tumor Antigens Expressed by Oncogene Transformed Cells
Funding Source:	NCI
Role:	PI
ID:	CA45187

Title:	Small compounds targeted to oncogenic k-ras/pkciota pathways an anticancer agent
Funding Source:	NIH/NCI
Role:	Consult

Title:	Phase I study of the BikDD Nanoparticle for Advanced Cancer of the Pancreas
Funding Source:	NIH/NCI
Role:	Consult

Title:	Preclinical development and testing of multifunctional tumor-targeted hybrid nanoparticles for lung cancer
Funding Source:	NIH/NIBIB
Role:	Other Significant Contributor
ID:	R03

Title:	Targeting KRAS mutant non-small cell lung cancer (NSCLC) in patient-derived xenografts (PDX) and developing strategies to overcome resistance to therapy
Funding Source:	MDACC & Mirati Therapeutics
Role:	Co-PI

Selected Publications

Peer-Reviewed Articles

Deboever, N, Al Tashi, Q, Eisenberg, M, Saad, M, Antonoff, MB, Hofstetter, WL, Mehran, RJ, Rice, DC, Roth, JA, Swisher, SG, Vaporciyan, AA, Walsh, GL, Wu, J, Rajaram, R. Machine Learning Prediction of Financial Toxicity in Patients with Resected Lung Cancer. Journal of the American College of Surgeons 241(2):107-116, 2025. e-Pub 2025. PMID: 40028915.
Deboever, N, Al Tashi, Q, Eisenberg, M, Saad, M, Antonoff, MB, Hofstetter, WL, Mehran, RJ, Rice, DC, Roth, JA, Swisher, SG, Vaporciyan, AA, Walsh, GL, Wu, J, Rajaram, R. Machine Learning Prediction of Financial Toxicity in Patients with Resected Lung Cancer. Journal of the American College of Surgeons 241(2):107-116, 2025. e-Pub 2025. PMID: 40028915.
Lei G, Sun M, Cheng J, Ye R, Lu Z, Horbath A, Huo D, Wu S, Alapati A, Aggarwal S, Xu Z, Mao C, Yan Y, Yao J, Li Q, Chen X, Lee H, Zhuang L, Jiang D, Pataer A, Roth JA, Navin N, Koong AC, You MJ, Lin SH, Gan B. Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. Cancer Cell 43(6):1076-1092.e5, 2025. e-Pub 2025. PMID: 40215978.
Wang Y, Meraz IM, Qudratullah M, Kotagiri S, Han Y, Xi Y, Wang J, Akdemir KC, Roth JA, Lissanu Y. Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. Cancer Res 85(11):1997-2013, 2025. e-Pub 2025. PMID: 40080526.
Meraz, I, Majidi, M, Song, R, Meng, F, Gao, L, Wang, Q, Wang, J, Shpall, E, Roth, JA. NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model. eLife 13, 2025. e-Pub 2025. PMID: 39932765.
Deboever N, Eisenberg MA, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Rajaram R. Relationship of Surgical Approach With Financial Toxicity in Patients With Resected Lung Cancer. J Surg Oncol 131(2):303-309, 2025. e-Pub 2025. PMID: 39257253.
Araujo HA, Pechuan-Jorge X, Zhou T, Do MT, Hu X, Rojas Alvarez FR, Salvatierra ME, Ibarguen HP, Lee R, Raghulan R, Shah H, Moreno Ayala MA, Chen K, Tovbis Shifrin N, Wu S, Solis Soto LM, Negrao MV, Gibbons DL, Hong DS, Roth JA, Heymach JV, Zhang J, Jiang J, Singh M, Smith JAM, Quintana E, Skoulidis F. Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC. Cancer Discov, 2024. e-Pub 2024. PMID: 38975897.
Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
Zhou, N, Leung, CH, William Jr, WN, Weissferdt, A, Pataer, A, Godoy, M, Carter, B, Fossella, FV, Tsao, A, Blumenschein, GR, Le, X, Zhang, J, Skoulidis, F, Kurie, JM, Altan, M, Lu, C, Glisson, BS, Byers, LA, Elamin, YY, Mehran, RJ, Rice, DC, Walsh, GL, Hofstetter, WL, Roth, JA, Tran, HT, Wu, J, Solis Soto, LM, Kadara, HN, Swisher, SG, Vaporciyan, AA, Gibbons, DL, Lin, HY, Jack Lee, J, Heymach, JV, Vailati Negrao, M, Sepesi, B, Cascone, T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. Journal for immunotherapy of cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
Zhou N, Leung CH, Wiliam WN, Weissferdt A, Pataer A, Fossella FV, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Wu J, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of Actionable Genomic Aberrations on Efficacy of Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. J Immunother Cancer, 2024. e-Pub 2024.
White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, Evrard YA, Chen L, Foroughi Pour A, Landua JD, Mashl RJ, Davies SR, Fang B, Raso MG, Evans KW, Bailey MH, Chen Y, Xiao M, Rubinstein JC, Sanderson BJ, Lloyd MW, Domanskyi S, Dobrolecki LE, Fujita M, Fujimoto J, Xiao G, Fields RC, Mudd JL, Xu X, Hollingshead MG, Jiwani S, Acevedo S, Davis-Dusenbery BN, Robinson PN, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Carvajal-Carmona LG, Welm AL, Welm BE, Govindan R, Li S, Davies MA, Roth JA, Meric-Bernstam F, Xie Y, Herlyn M, Ding L, Lewis MT, Bult CJ, Dean DA 2nd, Chuang JH. A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis. Cancer Res 84(13):2060-2072, 2024. e-Pub 2024. PMID: 39082680.
Deboever N, Correa AM, Feldman H, Eisenberg M, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL. Early Interventional Treatment of High Output Chyle Leak following Esophagectomy is Associated with Improved Survival. Ann Surg 280(1):91-97, 2024. e-Pub 2024. PMID: 38568206.
Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein LV, Welm AL, Dean DA, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm BE, Govindan R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona LG, Herlyn M, Davies MA, Shapiro GI, Fields RC, Trevino JG, Harrell JC, Doroshow JH, Chuang JH, Moscow JA. Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther, 2024. e-Pub 2024. PMID: 38641411.
White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, Evrard YA, Chen L, Foroughi pour A, Landua JD, Mashl RJ, Davies SR, Fang B, Rosa MG, Evans KW, Bailey MH, Chen Y, Xiao M, Rubinstein JC, Sanderson BJ, Lloyd MW, Domanskyi S, Dobrolecki LE, Fujita M, Fujimoto J, Xiao J, Fields RC, Mudd JL, Xu X, Hollingshead MG, Jiwani S, Acevedo S, Consortium P, Davis-Dusenbery BN, Robinson PN, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan C, Carvajal-Carmona LG, Welm AL, Welm BE, Govindan R, Li S, Davies MA, Roth JA, Meric-Bernstam F, Xie Y, Herlyn M, Ding L, Lewis MT, Bult CJ, Dean II DA, Chuang JH. A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis. Cancer Res 84(13):2060-2072, 2024. e-Pub 2024.
Tan X, Wang S, Xiao GY, Wu C, Liu X, Zhou B, Yu J, Duose DY, Xi Y, Wang J, Gupta K, Pataer A, Roth JA, Kim MP, Chen F, Creighton CJ, Russell WK, Kurie JM. Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer. J Clin Invest 134(12), 2024. e-Pub 2024. PMID: 38662435.
Deboever N, Feldman H, Eisenberg M, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL. Octreotide's role in the management of post-esophagectomy chylothorax. Dis Esophagus 37(6), 2024. e-Pub 2024. PMID: 38391198.
Haderk F, Chou YT, Cech L, Fernández-Méndez C, Yu J, Olivas V, Meraz IM, Barbosa Rabago D, Kerr DL, Gomez C, Allegakoen DV, Guan J, Shah KN, Herrington KA, Gbenedio OM, Nanjo S, Majidi M, Tamaki W, Pourmoghadam YK, Rotow JK, McCoach CE, Riess JW, Gutkind JS, Tang TT, Post L, Huang B, Santisteban P, Goodarzi H, Bandyopadhyay S, Kuo CJ, Roose JP, Wu W, Blakely CM, Roth JA, Bivona TG. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun 15(1):3741, 2024. e-Pub 2024. PMID: 38702301.
Feldman H, Sepesi B, Leung CH, Lin H, Weissferdt A, Pataer A, William WN, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical Outcomes After Chemotherapy plus Nivolumab and Chemotherapy plus Nivolumab and Ipilimumab in Patients with Non-Small Cell Lung Cancer. J Thorac Cardiovasc Surg 167(4):1444-1453.e4, 2024. e-Pub 2024. PMID: 37816395.
Deboever N, Bayley EM, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy. J Thorac Cardiovasc Surg 167(3):814-819.e2, 2024. e-Pub 2024. PMID: 37495170.
Deboever N, Eisenberg MA, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rajaram R. Perspectives, Risk Factors, and Coping Mechanisms in Patients with Self-Reported Financial Burden following Lung Cancer Surgery. J Thorac Cardiovasc Surg 167(2):478-487.e2, 2024. e-Pub 2024. PMID: 37356476.
Mitchell KG, Bayley EM, Ikoma N, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Erasmus JJ, Weston BR, Ajani JA, Badgwell BD, Hofstetter WL. Gastric extent of tumor predicts peritoneal metastasis in Siewert II adenocarcinoma. Ann Thorac Surg 117(2):320-326, 2024. e-Pub 2024. PMID: 37080372.
Deboever N, Bayley EM, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Do resected colorectal cancer patients need early chest imaging? Impact of clinicopathologic characteristics on time to development of pulmonary metastases. J Surg Oncol 129(2):331-337, 2024. e-Pub 2024. PMID: 37876311.
Deboever N, Correa AM, Feldman H, Mathur U, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Walsh GL, Vaporciyan AA, Antonoff MB, Rajaram R. Disparities in early-stage lung cancer outcomes at minority-serving hospitals compared with nonminority serving hospitals. J Thorac Cardiovasc Surg 167(1):329-337.e4, 2024. e-Pub 2024. PMID: 37116780.
Deboever N, Eisenberg M, Hofstetter WL, Mehran RJ, Rice DC, Roth J, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB, Rajaram R. Financial Toxicity in Patients With Resected Lung Cancer. Ann Surg 278(6):1038-1044, 2023. e-Pub 2023. PMID: 37249193.
Faron M, Cheugoua-Zanetsie M, Tierney J, Thirion P, Nankivell M, Winter K, Yang H, Shapiro J, Vernerey D, Smithers BM, Walsh T, Piessen G, Nilsson M, Boonstra J, Ychou M, Law S, Cunningham D, de Vathaire F, Stahl M, Urba S, Valmasoni M, Williaume D, Thomas J, Lordick F, Tepper J, Roth J, Gebski V, Burmeister B, Paoletti X, van Sandick J, Fu J, Pignon JP, Ducreux M, Michiels S, Group MC. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma. J Clin Oncol 41(28):4535-4547, 2023. e-Pub 2023. PMID: 37467395.
Deboever N, Eisenberg M, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth J, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB. Circulomic variables predict pathologic staging preoperatively in treatment-naïve non-small cell lung cancer. J Thorac Dis 15(10):5507-5516, 2023. e-Pub 2023. PMID: 37969292.
Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, Pataer A, Lu D, Han D, Malmberg E, Chan DW, Wang X, Savage SR, Mao S, Yu J, Peng F, Yan L, Meng H, Maneix L, Han Y, Chen Y, Yao W, Chang EC, Catic A, Lin X, Miles G, Huang P, Sun Z, Burt B, Wang H, Wang J, Yao QC, Zhang B, Roth JA, O'Malley BW, Ellis MJ, Rimawi MF, Ying H, Chen X. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science 381(6662):eabn4180, 2023. e-Pub 2023. PMID: 37676964.
Meraz IM, Majidi M, Fang B, Meng F, Gao L, Shao R, Song R, Li F, Lissanu Y, Chen H, Ha MJ, Wang Q, Wang J, Shpall E, Jung SY, Haderk F, Gui P, Riess JW, Olivas V, Bivona TG, Roth JA. Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol 6(1):608, 2023. e-Pub 2023. PMID: 37280434.
Bayley EM, Ivy ML, Shewale JB, Ge PS, Antonoff MB, Francis AM, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Vaporciyan AA, Walsh GL, Lee JJ, Louie BE, Swisher SG. High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for whom Surgery Should Not Be Delayed. Ann Surg 277(5):721-726, 2023. e-Pub 2023. PMID: 36052678.
Meraz IM, Majidi M, Fang B, Meng F, Gao L, Shao R, Song R, Li F, Lissanu Y, Chen H, Ha MJ, Wang Q, Wang J, Shpall E, Jung SY, Haderk F, Gui P, Riess JW, Olivas V, Bivona TG, Roth JA. 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol 6(1):509, 2023. e-Pub 2023. PMID: 37169941.
White B, Woo XY, Koc S, Sheridan T, Neuhauser S, Wang S, Evrard Y, Chen L, Landua J, Mashl R, Davies S, Fang B, Rasco MG, Evans K, Bailey M, Chen Y, Xiao M, Rubinstein J, Sanderson B, Foroughi pour A, Dobrolecki L, Fujita M, Fujimoto J, Xiao G, Rields R, Mudd J, Xu X, Hollingshead M, Jiwani S, Acevedo S, Davis-Dusenbery B, Robinson P, Wallace T, Moscow J, Doroshow J, Mitsiades N, Kaochar S, Pan CX, Chen M, Carvajal-Carmona L, Welm A, Welm B, Govindan R, Li S, Davies M, Roth J, Meric-Berstam F, Xie Y, Herlyn M, Li D, Lewis M, Bult C, Dean D, Chuang J. A pan-cancer PDX histology image repository with genomic and pathologic annotations for deep learning analysis. Cancer Res, 2023. e-Pub 2023.
Deboever N, Zhou N, McGrail DJ, Tomczak K, Oliva JL, Feldman HA, Parra E, Zhang J, Lee PP, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Swisher SS, Vaporciyan AA, Altan M, Weissferdt A, Tsao AS, Haymaker CL, Sepesi B. Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations. Front Oncol 13:1216999, 2023. e-Pub 2023. PMID: 37637041.
Zhou N, Hofstetter WL, Working Group ESCC, Mitchell KG, Bayley EM, Ajani JA, Antonoff MB, Betancourt SL, Blum-Murphy M, Feldman HA, Lin SH, Maru DM, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Weston BR. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg 114(6):2032-2040, 2022. e-Pub 2022. PMID: 34883083.
Feldman HA, Zhou N, Deboever N, Hofstetter W, Mehran R, Rajaram R, Rice D, Roth JA, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Godoy M, Strange C, Antonoff MB. Intraoperative challenges after induction therapy for non-small cell lung cancer: Effect of nodal disease on technical complexity. JTCVS Open 12:372-384, 2022. e-Pub 2022. PMID: 36590745.
Sepesi B, Zhou N, William WN, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 164(5):1327-1337, 2022. e-Pub 2022. PMID: 35190177.
Deboever N, Feldman HA, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB. The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era. J Surg Res 277:125-130, 2022. e-Pub 2022. PMID: 35489217.
Bayley EM, Zhou N, Mitchell KG, Antonoff MB, Mehran RJ, Rice DC, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Cinciripini PM, Karam-Hage M, Roth JA, Hofstetter WL. Modern Perioperative Practices May Mitigate Effects of Continued Smoking Among Lung Cancer Patients. Ann Thorac Surg 114(1):286-292, 2022. e-Pub 2022. PMID: 34358522.
Huang L, Wang J, Fang B, Meric-Bernstam F, Roth JA, Ha MJ. CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts. Sci Rep 12(1):12984, 2022. e-Pub 2022. PMID: 35906256.
Blumenthaler AN, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Strange CD, Antonoff MB. Preoperative Maximum Standardized Uptake Value Associated with Recurrence Risk In Early Lung Cancer. Ann Thorac Surg 113(6):1835-1844, 2022. e-Pub 2022. PMID: 34252403.
Koc S, Lloyd MW, Grover JW, Xiao N, Seepo S, Subramanian SL, Ray M, Frech C, DiGiovanna J, Webster P, Neuhauser S, Srivastava A, Woo XY, Sanderson BJ, White B, Lott P, Dobrolecki LE, Dowst H, Consortium P, Evrard YA, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Chen MS, Carvajal-Carmona L, Welm AL, Welm BE, Lewis MT, Govindan R, Ding L, Li S, Herlyn M, Davies MA, Roth J, Meric-Bernstam F, Robinson PN, Bult CJ, Davis-Dusenbery B, Dean DA, Chuang JH. PDXNet Portal: Patient-Derived Xenograft model, data, workflow, and tool discovery. NAR Cancer 4(2):zcac014, 2022. e-Pub 2022. PMID: 35475145.
Liu Y, Zhang Z, Rinsurongkawong W, Gay CM, Le X, Ning MS, Lewis J, Rinsurongkawong V, Lee JJ, Roth J, Swisher S, Gandhi S, Lee PP, Gibbons DL, Vaporciyan AA, Heymach JV, Zhang J, Lin SH. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Netw Open 5(6):e2215589, 2022. e-Pub 2022. PMID: 35666500.
Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
Zhou N, Corsini EM, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC. Robotic Surgery and Anatomic Segmentectomy: An Analysis of Trends, Patient Selection, and Outcomes. Ann Thorac Surg 113(3):975-983, 2022. e-Pub 2022. PMID: 33838123.
Deboever N, McGrail DJ, Lee Y, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Bernatchez C, Vailati Negrao M, Zhang J, Wistuba II, Heymach JV, Cascone T, Gibbons DL, Haymaker CL, Sepesi B. Surgical Approach Does Not Influence Changes in Circulating Immune Cell Populations Following Lung Cancer Resection. Lung Cancer 164:69-75, 2022. e-Pub 2022. PMID: 35038676.
Zhang X, Zhang R, Ren C, Xu Y, Wu S, Meng C, Pataer A, Song X, Zhang J, Yao Y, He H, Chen H, Ma W, Wang J, Meric-Bernstam F, Champlin RE, Heymach JV, Rooney CM, Swisher SG, Vaporciyan AA, Roth JA, You MJ, Wang ML, Fang B. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv, 2022. e-Pub 2022. PMID: 34861697.
Shah P, Forget MA, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, JAb B, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker CL, McGrail DJ, Reuben A, Bernatchez C. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer 10(2), 2022. e-Pub 2022. PMID: 35110355.
Meraz IM, Majidi M, Shao R, Meng F, Ha MJ, Shpall E, Roth JA. TUSC2 immunogene enhances efficacy of chemoimmuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model. Commun Biol 5(1):167, 2022. e-Pub 2022. PMID: 35210547.
Zhou N, Rice DC, Tsao AS, Lee PP, Haymaker CL, Corsini EM, Antonoff MB, Hofstetter WL, Rajaram R, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Mehran RJ, Sepesi B. Extrapleural Pneumonectomy versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Ann Thorac Surg 113(1):200-208, 2022. e-Pub 2022. PMID: 33971174.
Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer. Ann Oncol 33(1):42-56, 2022. e-Pub 2022. PMID: 34653632.
Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, Consortium NCI, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nat Commun 13(1):294, 2022. e-Pub 2022. PMID: 34996889.
Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F. Combined MEK/MDM2 Inhibition Demonstrates Antitumor Efficacy in TP53 Wild-Type Thyroid and Colorectal Cancers with MAPK Alterations. Sci Rep 12(1):1248, 2022. e-Pub 2022. PMID: 35075200.
Rice D, Rodriguez-Restrepo A, Mena G, Cata J, Thall P, Milton D, Correa A, Woodard T, Antonoff M, Hofstetter W, Roth J, Sepesi B, Swisher S, Walsh G, Vaporciyan A, Mehran R. Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery. Ann Surg 274(6):1099-1106, 2021. e-Pub 2021. PMID: 32229762.
Chang JY, Verma V, Feng L, Roth JA. SABR for operable stage I non-small-cell lung cancer: comparison to surgery - Authors' reply. Lancet Oncol 22(12):e537-e538, 2021. e-Pub 2021. PMID: 34856147.
Corsini EM, Foo WC, Mitchell KG, Zhou N, Maru DM, Ajani JA, Hofstetter WL, Working Group EA, Correa AM, Antonoff MB, Lin SH, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg 162(5):1404-1412.e2, 2021. e-Pub 2021. PMID: 33010880.
Faron M, Cheugoua-Zanetsie AM, Thirion P, Nankivell M, Winter K, Cunningham D, Van der Gaast A, Law S, Langley R, de Vathaire F, Valmasoni M, Mauer M, Roth J, Gebski V, Burmeister BH, Paoletti X, van Sandick J, Fu J, Ducreux M, Blanchard P, Tierney J, Pignon JP, Michiels S, group MC. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. Eur J Cancer 157:278-290, 2021. e-Pub 2021. PMID: 34555647.
Zhou N, Mitchell KG, Corsini EM, Truong VTT, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Ajani JA, Hofstetter WL. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma. Br J Surg 108(10):1207-1215, 2021. e-Pub 2021. PMID: 34095952.
Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA, Trials Group SLC. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 22(10):1448-1457, 2021. e-Pub 2021. PMID: 34529930.
Corsini EM, Mitchell KG, Zhou N, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL. Intestinal Metaplasia in the Esophageal Remnant is Rare after Ivor Lewis Esophagectomy. J Gastrointest Surg 25(9):2185-2191, 2021. e-Pub 2021. PMID: 33555525.
Corsini EM, Mitchell KG, Zhou N, Bernatchez C, Forget MA, Haymaker CL, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Amaria RN, Jazaeri AA, Antonoff MB. Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility. J Surg Oncol 124(4):699-703, 2021. e-Pub 2021. PMID: 34057733.
Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, Consortium NCI, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nat Commun 12(1):5086, 2021. e-Pub 2021. PMID: 34429404.
Corsini EM, Mitchell KG, Zhou N, Antonoff MB, Mehran RJ, Mena GE, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC, Hofstetter WL. Liposomal Bupivacaine Intercostal Block is Important for Reduction of Pulmonary Complications. Ann Thorac Surg 112(2):423-429, 2021. e-Pub 2021. PMID: 33129774.
Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
Corsini EM, Mitchell KG, Correa A, Morris VK, Antonoff MB, Group MD. Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy. J Thorac Cardiovasc Surg, 2021. e-Pub 2021. PMID: 32713636.
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, Consortium P, Consortium E. Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53(5):761, 2021. e-Pub 2021. PMID: 33608693.
Corsini EM, Mitchell KG, Zhou N, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Lin SH, Ajani JA, Hofstetter WL. Modified En bloc Esophagectomy Compared to Standard Resection after Neoadjuvant Chemoradiation. Ann Thorac Surg 111(4):1133-1140, 2021. e-Pub 2021. PMID: 32857997.
Corsini EM, Zhou N, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL. Postoperative Bleeding and Acute Kidney Injury in Esophageal Cancer Patients Receiving Ketorolac. Ann Thorac Surg, 2021. e-Pub 2021. PMID: 32980327.
Lam VK, Zhang J, Wu CC, Tran HT, Li L, Diao L, Wang J, Rinsurongkawong W, Raymond VM, Lanman RB, Lewis J, Roarty EB, Roth J, Swisher S, Lee JJ, Gibbons DL, Papadimitrakopoulou VA, Heymach JV. Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC. J Thorac Oncol, 2021. e-Pub 2021. PMID: 33388476.
Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporiciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target. J Thorac Oncol, 2021. e-Pub 2021. PMID: 33388477.
Schwalk AJ, Ost DE, Saltijeral SN, De La Garza H, Casal RF, Jimenez CA, Eapen GA, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Elamin Y, Zhang J, Roth JA, Swisher S, Heymach JV, Grosu HB. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest 159(3):1256-1264, 2021. e-Pub 2021. PMID: 33217413.
Sitthideatphaiboon P, Galan-Cobo A, Negrao MV, Qu X, Poteete A, Zhang F, Liu DD, Lewis WE, Kemp HN, Lewis J, Rinsurongkawong W, Giri U, Lee JJ, Zhang J, Roth JA, Swisher S, Heymach JV. LKB1 mutations in NSCLC are associated with KEAP1/NRF2-dependent radiotherapy resistance targetable by glutaminase inhibition. Clin Cancer Res 27(6):1720-1733, 2021. e-Pub 2021. PMID: 33323404.
Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(3):346-360.e7, 2021. e-Pub 2021. PMID: 33482121.
Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
Corsini EM, Hofstetter WL, Group MD. Ketorolac use and anastomotic leak in patients with esophageal cancer. J Thorac Cardiovasc Surg, 2021. e-Pub 2021. PMID: 32340809.
Yuan G, Flores NM, Hausmann S, Lofgren SM, Kharchenko V, Angulo-Ibanez M, Sengupta D, Lu X, Czaban I, Azhibek D, Vicent S, Fischle W, Jaremko M, Fang B, Wistuba II, Chua KF, Roth JA, Minna JD, Shao NY, Jaremko L, Mazur PK, Gozani O. Elevated NSD3 Histone Methylation Activity Drives Squamous Cell Lung Cancer. Nature 590(7846):504-508, 2021. e-Pub 2021. PMID: 33536620.

Professional Educational Materials

Roth J. Gene therapy for lung therapy. (Videoconference). Satellite patient information network, 1996.
Roth J. p53 gene therapy for lung cancer. (Audio Journal of Oncology), 1996.
Roth J. The technique of esophagectomy does not influence survival after resection of esophageal carcinoma. (Video Library). International Society for Diseases of the Esophagus (ISDE, 1995.
Roth J. Results of esophagectomy for severe dysplasia in Barrett‘s esophagus. (Video Library). International Society for Diseases of the Esophagus (ISDE), 1995.
Roth J. Biology of non-small cell lung cancer. The Current Perspectives in the Treatment of Non-Small Cell Lung Cancer, The University of Colorado Health Sciences Center, 1994.
Roth J. Commentary and Review of presentations on lung cancer. (Audio Cassettes). American Society of Clinical Oncology - IASLC Update: Commentary on Lung Cancer Presentations, 1994.
Roth J. Surgical and neoadjuvant approaches to locally advanced, potentially resectable non-small cell lung cancer. Recent Advances in the Management of Lung Cancer, The University of Texas Southwestern Medical Center, 1993.
Roth J. Brief Report: Modulation of oncogene and tumor suppressor gene expression for prevention and therapy of lung cancer. Invited Symposia Speaker, 4th IASLC Lung Tumor Biology Workshop, 1993.
Roth J. Molecular biology of NSCLC. Advances in the Diagnosis and Treatment of Lung Cancer, University of California, Los Angeles, School of Medicine, 1992.
Roth J. Esophageal cancer (multidisciplinary). American Society of Clinical Oncology Fall Educational Conference, 1992.
Roth J. The biology and therapy of adenocarcinoma of the esophagus and cardia. American Society of Clinical Oncology Educational Program, 1992.
Roth J. Surgical therapy for stage I and stage II non-small cell lung cancer. American College of Chest Physicians, Postgraduate Course, Lung Cancer: Internist and Surgeon, 1991.
Roth J. Tumor biology. American College of Chest Physicians, Postgraduate Course, Lung Cancer: Internist and Surgeon, 1991.
Roth J. Practical reviews in cancer management: Cancer of the esophagus (Audio Cassette Tape). Albert Einstein College of Medicine, 1991.
Roth J. Adjuvant therapy for esophageal carcinoma. (Manual). Southern Thoracic Surgical Association 37th Annual Meeting Postgraduate Course, 1990.
Roth J. New insights into selecting patients likely to benefit from resection of pulmonary metastases. (Manual). American College of Surgeons Postgraduate Course, 1990.
Roth J. Carcinoma of the esophagus. (Manual). Educational Symposium for the American Society of Clinical Oncology, 1990.
Roth J. Symposium on thoracic surgical oncology (September 1989) Educational Report of Proceedings of the 25th Anniversary Meeting of the Society of Thoracic Surgeons held by the Thoracic Surgery Directors Association. (Manual). Ann Thorac Surg, 1990.
Roth J. New developments in management of lung cancer. (Audio tape with CME Credit, 120 minutes). Oncology Update, 1990.
Roth J. Prognostic indicators for soft tissue sarcoma in patients with pulmonary metastases. (Manual). American College of Surgeons Postgraduate Course, 1989.
Roth J. Cancer-induced immunosuppression: Implications for therapy. (Manual). American College of Surgeons Postgraduate Course, Seminars in Surgical Oncology, 1988.
Roth J. Obliteration of bronchopleural fistula in a pneumonectomized lymphoma patient by tailored thoracoplasty and muscle transposition. (Motion Picture). American College of Surgeons, New Orleans, LA, and Society of Thoracic Surgeons, 1987.
Roth J. Resection of the unresectable chest wall rhabdomyosaroma following multi-modality treatment. (Motion Picture). American College of Surgeons, Chicago, IL, and Society of Thoracic Surgeons, 1985.

Abstracts

Eisenberg MA, Deboever N, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB. Pulmonary Surgical Margins for Metastatic Osteosarcoma: Is Negative Margin Enough?. STSA 2023, 2023. e-Pub 2023.
Eisenberg MA, Deboever N, Antonoff MB, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL. A Propensity Matched Analysis. STSA 2023, 2023. e-Pub 2023.
Deboever N, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB. Extent of Resection in Stage IV Non-small Cell Lung Cancer: Does it Even Matter?. International Thoracic Surgical Oncology Summit, 2023. e-Pub 2023.
Deboever N, Bayley EM, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy. International Thoracic Surgical Oncology Summit, 2023. e-Pub 2023.
Graber W, Deboever N, Niu J, Eisenberg M, Antonoff M, Hofstetter W, Mehran R, Roth J, Sepesi B, Swisher S, Walsh G, Vaporciyan A, Giordano S, Rajaram R, Rice D. Evaluating The Conditional Survival Benefit Of Minimally Invasive Lobectomy In Early-stage Non-small Cell Lung Cancer. 2023 Annual Meeting of the International Society for Minimally Invasive Cardiothoracic Surgery, 2023. e-Pub 2023.
Deboever N, Eisenberg MA, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rajaram R. Perspectives, Risk Factors, and Coping Mechanisms in Patients with Self-Reported Financial Burden following Surgical Management of Non-Small Cell Lung Cancer. AATS 2023, 2023. e-Pub 2023.
Sepesi B, Feldman H, Walsh GL, Rice, DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Gibbons DL, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical Outcomes After Chemotherapy plus Nivolumab and Chemotherapy plus Nivolumab and Ipilimumab in Patients with Non-Small Cell Lung Cancer. AATS 2023, 2023. e-Pub 2023.
Deboever N, Al-Tashi Q, Eisenberg M, Hofstetter W, Mehran R, Rice D, Roth J, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Mara A, Wu J, Rajaram R. Machine learning prediction of financial toxicity in patients with resected lung cancer. AACR 2023, 2023. e-Pub 2023.
White B, Woo XY, Koc S, Sheridan T, Neuhauser S, Wang S, Evrard Y, Chen L, Landua J, Mashl R, Davies S, Fang B, Rasco MG, Evans K, Bailey M, Chen Y, Xiao M, Rubinstein J, Sanderson B, Foroughi pour A, Dobrolecki L, Fujita M, Fujimoto J, Xiao G, Rields R, Mudd J, Xu X, Hollingshead M, Jiwani S, Acevedo S, Davis-Dusenbery B, Robinson P, Wallace T, Moscow J, Doroshow J, Mitsiades N, Kaochar S, Pan CX, Chen M, Carvajal-Carmona L, Welm A, Welm B, Govindan R, Li S, Davies M, Roth J, Meric-Berstam F, Xie Y, Herlyn M, Li D, Lewis M, Bult C, Dean D, Chuang J. A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis. AACR Annual Meeting 2023, 2023. e-Pub 2023.
Ries SA, Qing Y, Sun R, Eisenberg MA, Mitchell KG, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB. Disparities in Lung Cancer Surgery Permeate Evolving Paradigms in Stage IV Disease. AATS 2023, 2023. e-Pub 2023.
Deboever N, Khanduri I, Eisenberg M, Mehran RJ, Rajaram R, Rice DC, Roth J, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB, Maru DM, Hofstetter WL. Mucosal Lymphovascular Invasion in Early Esophageal Cancer; Depth of LVI Affects Outcome. AATS 2023, 2023. e-Pub 2023.
Deboever N, Bayley, EM, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Optimal Timing for Surveillance Imaging in Colorectal Pulmonary Metastatic Disease: Evidence for a Clinicopathologic-driven Algorithm. International Thoracic Surgical Oncology Summit, 2022. e-Pub 2022.
Deboever N, Bayley EM, Feldman HA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Do Resected Colorectal Cancer Patients Need Early Chest Imaging? Impact of Clinicopathologic Characteristics on Time to Development of Pulmonary Metastases. American College of Surgeons Clinical Congress, 2022. e-Pub 2022.
Deboever N, Bayley EM, Feldman HA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Lymph Node Ratio is Associated with Time to Pulmonary Metastasis in Patients with Resected Colorectal Cancer. American College of Surgeons Clinical Congress, 2022. e-Pub 2022.
Deboever N, Eisenberg M, Hofstetter W, Mehran R, Rajaram R, Rice D, Roth J, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Antonoff M. Circulomic Variables may Predict Pathologic Staging Preoperatively in Treatment-Naïve Non-Small Cell Lung Cancer. 2022 North America Conference on Lung Cancer, 2022. e-Pub 2022.
Deboever N, Bayley EM, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Surveillance following Colorectal Cancer Pulmonary Metastasectomy should be Dependent on Clinicopathologic Factors. International Thoracic Surgical Oncology Summit 2022, 2022. e-Pub 2022.
Deboever N, Mitchell KG, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB, Sepesi B. Aspirin’s Protective Effect in Resectable Non-Small Cell Lung Cancer is Marginally Mediated by Circulomics. International Thoracic Surgical Oncology Summit, 2022. e-Pub 2022.
Eisenberg MA, Deboever N, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB. The Pre-Operative Inflammasome Predicts Infectious Complications Following Lung Resection in Patients with NSCLC. International Thoracic Surgical Oncology Summit, 2022. e-Pub 2022.
Bayley EM, Ivy ML, Ge PS, Shewale JB, Antonoff MB, Francis AM, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Vaporciyan AA, Walsh GL, Lee JJ, Louie BE, Swisher SG. High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for whom Surgery Should Not Be Delayed. Digestive Diseases Week Annual Meeting 2022, 2022. e-Pub 2022.
Mitchell KG, Bayley EM, Ikoma N, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Erasmus JJ, Weston BR, Ajani JA, Badgwell BD, Hofstetter WL. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. 102nd Annual Meeting of the American Association for Thoracic Surgery, 2022. e-Pub 2022.
DiPeri TP, Evans K, Kong K, Raso G, Rizvi Y, Zheng X, Ha MJ, Chen H, Korkut A, Buchold G Kirby B, Dumbrava EI, Pant S, Ajani JA, Roth JA, Rowse G, Rodon J, Meric-Bernstam F. Co-Clinical Trial of Patient-Derived Xenograft Models from the Phase I Trial of Bispecific Anti-HER2 Antibody Zanidatamab. SSO 2022, 2022. e-Pub 2022.
Deboever N, Correa A, Feldman HA, Eisenberg MA, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL. Early Interventional Treatment of High Output Chyle Leak following Esophagectomy is Associated with Improved Survival. STS 2022, 2022. e-Pub 2022.
Feldman HA, Zhou N, Deboever N, Hofstetter W, Mehran R, Rajaram R, Rice D, Roth JA, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Godoy M, Strange C, Antonoff MB. Intraoperative Challenges After Induction Therapy for NSCLC: Impact of Nodal Disease on Technical Complexity. AATS 2022, 2022. e-Pub 2022.
Deboever N, Bayley EM, Bednarski BK, Morris VK, Antonoff MB, Group MD. Lymph Node Ratio is Associated with Time to Pulmonary Metastasis in Patients with Resected Colorectal Cancer. American College of Surgeons Clinical Congress 2022, 2022. e-Pub 2022.
Hubert SM, Li Z, Zhang R, Song X, Karpinets T, Weissferdt A, Little L, Mohammad M, Gumbs C, Negrao M, Zhang J, Pataer A, Swisher S, Vaporciyan A, Roth J, Heymach J, Sepesi B, Gibbons D, Fang B, Zhang J. Molecular Parameters Impacting the Success Rate of a Lung Cancer PDX Model. ASCO 2022, 2022. e-Pub 2022.
Deboever N, Feldman H, Vaporciyan A, Hofstetter W, Roth J, Mehran R, Swisher S, Walsh G, Rajaram R, Rice D, Antonoff M. The Role of Surgery in the Treatment of Pulmonary Melanoma Metastases Amidst Modern Systemic Therapies. Academic Surgical Congress 2022, 2022. e-Pub 2022.
Blumenthaler AN, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Strange CD, Antonoff MB. Preoperative Maximum Standardized Uptake Value Associated with Recurrence Risk In Early Lung Cancer. STS 2022, 2022. e-Pub 2022.
Frank ML, Shah P, Forget MA, Federico L, Jiang P, Khairullah R, Wistuba II, Chow CW, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth J, Zhaing J, Sepesi B, Gibbons DL, Heymach JV, Haymaker C, McGrail DJ, Bernatchez C, Reuben A. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. SITC 2021, 2021. e-Pub 2021.
Chang JY, Mehran RJ, Feng L, Balter P, McRae S, Berry DA, Roth JA, Trials Group SC. Stereotactic ablative radiotherapy in operable stage I NSCLC patients: Long-term results of the expanded STARS clinical trial. ASCO 2021, 2021. e-Pub 2021.
Faron M, Cheugoua-Zanetsie AM, Nankivell MG, Winter KA, Law S, Van Der Gaast A, Ychou M, Mauer M, Valmasoni M, Roth JA, Blanchard P, Thirion PG, Tierney JF, Gebski V, Burmeister BH, Paoletti X, Yang H, Van Sandick JW, Ducreux M, Michiels S. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma. ASCO 2021, 2021. e-Pub 2021.
Li D, Ha MJ, Evrard YA, Chen H, McShane LM, Grover J, Wang J, Fang B, DiPeri T, Lewis MT, Rubinstein L, Roth JA, Chuang JH, Doroshow JH, Moscow JA, Meric-Bernstam F. A systematic review of the tumor growth metrics of patient-derived xenograft (PDX) models in the literature and in NCI PDXNet centers. AACR 2021, 2021. e-Pub 2021.
Gay CM, Stewart CA, Diao L, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Vokes NI, Ramkumar K, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Minna J, Heymach JV, Byers LA. A novel, inflamed small cell lung cancer transcriptional subtype, SCLC-I, defines a subset of patients with distinct immunotherapy vulnerability. AACR 2021, 2021. e-Pub 2021.
Lazo G, Yao JC, Najam AA, Swisher SG, Putnam JB, Roth JA, Mansfield PF, Pisters PW, Ajani JA. Clinical risk factors for peritoneal metastases in esophagogastric junction carcinoma (GEJC). Proc Am Soc Clin Oncol 21:141a, 2002. e-Pub 2002.
Pataer A, Chada S, Hunt KK, Roth JA, Swisher SG. Adenoviral MDA-7 induces apoptosis in lung cancer cells through mitochondrial permeability transition independent cytochrome C release. Proc Am Assoc Thor Surg 82:40, 2002. e-Pub 2002.
Kataoka M, Schumacher G, Cristiano RJ, Atkinson NE, Fujiwara T, Tanaka N, Roth JA, Mukhopadhyay T. Systemic delivery of adenovirus-p53 with 2-methoxyestradiol inhibits lung metastasis in nude mice. Lung Cancer 29:121, 2000. e-Pub 2000.

Book Chapters

Tsao A, Roth JA. 31Novel Emerging Agents in NSCLC (including gene therapy). In: Lung Cancer. 4th. Wiley-Blackwell Health Sciences, 479-487, 2014.
Sobol RE, Guan YS, Li LJ, Zhang WW, Peng Z, Menander KB, Chada S, Zumstein LA, Maneval DC, Horowitz JA, Warren R, Clayman GL, Swisher SG, Goodman WJ, Nemunaitis J, Roth JA. p53 Gene Therapy for Cancer Treatment and Prevention. In: p53 In the Clinics. Springer, 189-208, 2013.
Mehran R, Roth JA. Resection of pulmonary metastases. In: Atlas of Advanced Operative Surgery. 1st. Elsevier, Inc, 43-49, 2013.
Shirvani SM, Chang JY, Roth JA. Can stereotactic body radiation therapy (SBRT) in early stage lung cancers produce comparable success as surgery?. In: Thoracic Surgery Clinics - Lung Cancer, Part II: Surgery and Adjuvant Therapies. Elsevier Publishers, 369-381, 2013.
Roth JA, Chang JY. An Issue of Thoracic Surgery Clinics. In: Thoracic Surgery Clinics, devoted to Lung Cancer, Part II: Surgery and Adjuvant Treatment. Elsevier, 2013.
Kuroda S, Yokoyama T, Tam JO, Scott AW, Ma LL, Shanker M, Roth JA, Sokolov K, Johnston KP, Ramesh R. Multifunctional tumor-targeted nanoparticles for lung cancer. In: Pulmonary Nanomedicine: Diagnostic, Imaging and Therapeutics. Pan Stanford Publishing PTE Ltd, 15-44, 2012.
Ji L, Jayachandran G, Roth JA. High throughput profiling of serum phosphoproteins/peptides using the SELDI-TOF-MS platform. In: SELDI-TOF Mass Spectrometry: Methods in Molecular Biology. Chapter 14. Humana Press, 2012.
Jayachandran G, Roth J, Ji L. Analysis of Protein-Protein Interaction Using ProteinChip Array-Based SELDI-TOF Mass Spectrometry. In: SELDI-TOF Mass Spectrometry: Methods in Molecular Biology. Chapter 15. Humana Press, 2012.
Ramesh R, Shanker M, Jin J, West S, Roth JA. Lipid-based nanocarriers for cancer gene therapy. In: Lipid Nanocarriers in Cancer Diagnosis and Therapy. iSmithers-Creative Publishing Solutions, 169-188, 2011.
Allen M, Cerfolio R, Darling G, Deslauriers J, Duranceau A, Ferguson M, Finley R, Johnston M, Krasna M, Lerut T, Luketich J, Mathisen D, McKenna R, Pearson G, Reed C, Roth J, Rusch V, Sugarbaker D, Ximenes M, Yim A. Building a successful career: Advice from leaders in thoracic surgery. In: Thoracic Surgery Clinics. Elsevier, 395-415, 2011.
Ramesh R, Ioannides CG, Roth JA, Chada S. Adenovirus-Mediated Interleukin (IL)-24 Immunotherapy for Cancer. In: Methods Mol Biol. Humana Press, 241-70, 2010.
Roth JA. Cancer of the Lung. In: Cancer Medicine. 8th, 999-1043, 2010.
Lu C, Onn A, Vaporciyan AA, Chang JY, Glisson BS, Komaki R, Wistuba II, Roth JA, Herbst Roy S. Cancer of the Lung. In: Cancer Medicine. 8th, 999-1043, 2010.
Nemunaitis J, Roth JA. Gene-Based Therapies for Lung Cancer. In: Lung Cancer: Prevention, Management and Emerging Therapies. Springer, 305-330, 2009.
Nemunaitis J, Roth J. Vaccine Therapy for Lung Cancer. In: Lung Cancer. Springer, 279-304, 2009.
Roth JA. Gene Therapy Approaches for Lung Cancer. In: Molecular Pathology of Lung Diseases. Springer, 219-225, 2008.
Fang B, Roth JA. Tumor-suppressor gene replacement therapy. In: Viral Therapy of Cancer. John Wiley & Sons, Ltd, 229-239, 2008.
Fang B, Roth JA. Adenovector-mediated cancer gene therapy. Chapter 1. In: Cancer Drug Discovery and Development: Gene Therapy for Cancer, 3-22, 2007.
Chang JY, Komaki R, Roth JA, Jr HR, Cox JD. Image guidance of combined modality management of NSCLC. In: Image-guided radiation therapy for lung cancer. US Books and Journals, 1-14, 2007.
Chada S, Bocangel D, Pataer A, Mhashilkar AM, Inoue S, Miyahara R, Roth JA, Grimm EA, Swisher SG, Hunt KK, Ramesh R. MDA-7/IL-24 as a multi-modality therapy for cancer. Chapter 23. In: Cancer Drug Discovery and Development: Gene Therapy of Cancer. Humana Press, Inc, 413-434, 2007.
Roth JA. Targeted genetic therapy for lung cancer. In: Lung Cancer. 3rd. Blackwell Scientific Publishers, 411-420, 2007.
Chada S, Bocangel D, Menander K, Roth JA. Apoptosis modulators: p53 targeting. In: Targeted Therapies in Oncology. Informa Healthcare USA, Inc. – New York, London - Health Science Division of Taylor and Francis Group, 177-195, 2007.
Chang JY, Roth JA. Stereotactic body radiation therapy for stage I non-small cell lung cancer. In: Thorac Surg Clin. 2. Elsevier, 251-260, 2007.
Mehran R, Roth JA. Resection of pulmonary metastases (open/thorascopic). In: Atlas of Advanced Operative Surgery. Elsevier, Inc, 2007.
Chada S, Menander KB, Roth J, Ramesh R. Targeting cancer with tumor suppressor genes. In: Gene Therapy. Medical View Co. Ltd, 266-278, 2007.
Roth JA. Gene therapy for lung cancer. Chapter 36. In: Tumors of the chest: biology, diagnosis, and management. 1st. Springer Verlag, 431-435, 2006.
Moon C, Lee J, Par, Roth JA. . Current status of gene therapy for lung cancer and head and neck cancer. In: About Cancer in Africa. Instut National du Cancer, 673-703, 2006.
Onn A, Vaporciyan AA, Chang JY, Komaki R, Roth JA, Herbst R. Cancer of the lung. Chapter 7. In: Cancer Medicine. Williams & Wilkins, 1179-1225, 2005.
Roth JA, Grammer SF. Tumor suppressor gene replacement for cancer. Chapter 3. In: Contemporary Cancer Research Cancer Gene Therapy. 1st. Humana Press Inc, 19-33, 2005.
Roth JA. Genetics and molecular biology of lung cancer. In: Encyclopedia of Molecular Cell Biology and Molecular Medicine. 2nd Fung-Grow. Wiley-VCH Verlag GmbH & Co. KGaA, 353-368, 2004.
Roth JA, Grammer SF, Merritt JA, Swisher SG. Gene therapy clinical trials for cancer: replacement of tumor suppressor gene, p53 Chapter 38. In: Gene and Cell Therapy. 2nd. Marcel Dekker, Inc, 743-752, 2004.
Roth JA Grammer SF. Tumor suppressor gene therapy, Regulation, Function and Medicinal Applications. In: Methods in Molecular Biology. Humana Press, Inc, 577-598, 2003.
Vaporciyan AA, Kies M, Stevens C, Komaki R, Roth JA. Cancer of the lung. In: Cancer Medicine. BC Decker Inc, 1385-1446, 2003.
Putnam JB, Roth JA. Pulmonary metastases. In: Surgical Oncology: Multidisciplinary Approach to Difficult Problems. Arnold Publishers, 742-764, 2002.
Roth JA, Grammer SF, Merritt J, Swisher SG. Gene therapy clinical trials for cancer: replacement of tumor suppressor gene p53. In: Gene and Cell Therapy Therapeutic Mechanisms and Strategies. 2nd. Marcel Dekker, Inc, 743-752, 2002.
Swisher SG, Roth JA. Adenoviral p53 gene therapy strategies in non small-cell lung cancer, Chapter 19. In: Chemoradiation in Cancer Therapy. Humana Press, Inc, 349-358, 2002.
Fang B, Roth JA. Gene therapy. In: Molecular Basis of Cancer. 2nd. WB Saunders Company, 589-604, 2001.
Roth JA. Gene therapy approaches for the management of cancer. In: ASCO Spring Education Book, 558-5645, 2001.
Roth JA, Grammer SF. Gene therapy: tumor suppressor gene replacement and oncogene suppression, Chapter 98. In: The Cancer Handbook. MacMillan, 1521-1531, 2001.
Swisher SG, Grammer SF, Roth JA. Ad-p53 gene transfer strategies for non-small-cell lung cancer. In: American Society of Clinical Oncology, 412-417, 2001.
Roth JA. Lung Cancer "Biology of Lung Cancer" Chapter 31. In: Thoracic Surgery. Elsevier, 772-783, 2001.
Fang B, Roth JA. Gene therapy using direct in vivo gene injection. In: Principles and Practice of the Biologic Therapy of Cancer. 3rd. Lippincott Williams & Wilkins, 796-810, 2000.
Roth JA, Molldrem J, Smythe R. The current status of cancer gene therapy trials Chapter 13. In: Cancer: Principles & Practice of Oncology. 2nd. Lippincott-Raven, 2-15, 2000.
Vaporciyan AA, Nesbitt JC, Lee JS, Stevens C, Komaki R, Roth JA. Cancer of the lung. In: Cancer Medicine. 5th. Decker Inc, 1227-1292, 2000.
Roth JA. Cancer Biology. In: Thoracic Surgery Esophageal Surgery. 2nd. WB Saunders Co, 637-647, 1999.
Pollock RE, Balch CM, Roth JA, McPeek B, Mosteller F. Formulating an initial research plan. In: Surgical Research: Basic Principles and Clinical Practice. Third. Springer, 363-365, 1998.
Mukhopadhyay T, Roth JA. Ribozymes in targeting tumor suppressor genes. In: Ribozymes in the Gene Therapy of Cancer. RG Landes Co, 175-182, 1998.
Roth JA. The molecular biology of lung cancer. In: The Encyclopedia of Molecular Biology. Chernow Editorial Services, Inc, 1998.
Roth JA. Genetic manipulations for the treatment of lung cancer. In: Lung Cancer. Blackwell Science Inc, 369-381, 1998.
Roth JA. Defective tumor suppressor gene replacement and oncogene inactivation for the treatment of cancer. In: Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. Marcel Dekker, Inc, 279-294, 1998.
Schrump DS, Roth JA. Gene therapy of lung cancer. In: Biology of Lung Cancer. Marcel Dekker, Inc, 171-185, 1998.
Swisher SG, Roth JA. Role of gene therapy in lung cancer. In: Advanced Therapy in Thoracic Surgery. Marcel Decker, Inc, 139-145, 1998.
Cristiano RJ, Nguyen D, Spitz F, Roth JA. Gene therapy: its interactions with chemotherapy. In: Infusion chemotherapy-irradiation interactions. Elsevier Science, 175-182, 1998.
Maxwell SA, Roth JA. Oncogene interactions with tumor suppressor genes. In: Encyclopedia of Cancer. Academic Press, Inc, 1161-1171, 1997.
Mukhopadhyay T, Roth JA. Isolation of total RNA from tissues or cell lines: visualization in Gel. In: Methods in Molecular Biology: RNA Isolation and Characterization Protocols. Humana Press Inc, 55-59, 1997.
Jr PJ, Morris P, Roth JA. Esophageal carcinoma. In: Difficult Problems in Surgical Oncology. Chapman & Hill, 1997.
Zhang WW, Roth JA. Methods for cancer gene therapy using tumor suppressor genes. In: Gene Therapy Protocols. Humana Press, 403-418, 1997.
Ajani JA, Roth JA, Ryan B, McMurtrey M, Rich TA. Resectable adenocarcinoma of the esophagus: a study of pre- and postoperative chemotherapy. In: Adjuvant Therapy of Cancer VI. WB Saunders Co, 396-404, 1996.
Balch CM, Milton GW, Roth JA. Surgery for metastatic melanoma. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. JB Lippincott Co, 1996.
Nesbitt JC, Lee JS, Komaki R, Roth JA. Cancer of the Lung. In: Cancer Medicine. Williams & Wilkins, 3-83, 1996.
Roth JA. Gene replacement strategies for prevention and treatment of aerodigestive tract cancers. In: Accomplishments in Cancer Research. JB Lippincott Co, 188-199, 1996.
Roth JA. Lung cancer, molecular biology of. In: Encyclopedia of Molecular Biology and Molecular Medicine. VCH Verlagsesellschaft, 491-497, 1996.
Roth JA, Mukhopadhyay T, Casson AG, Chung KY. Molecular strategies for the prevention and therapy of cancer. In: Gene Therapy of Cancer. Appleton and Lange, 1996.
Roth JA, Putnam Jr JB. Pulmonary resection for metastatic disease. In: Difficult Problems in Surgical Oncology. Chapman and Hill, 1996.
Roth JA, Jr PJ, Rich TA, Forastiere AA. Cancer: cancer of the esophagus. In: Cancer: Principles and Practices of Oncology. Lippincott – Raven Press, 980-1010, 1996.
Ajani JA, Kelsen DP, Rich TA, Roth JA. Chemotherapy and combined modality therapy for squamous cell carcinoma and adenocarcinoma of the esophagus and gastroesophageal junction. In: Anonymous Thoracic Oncology. WB Saunders, 433-441, 1995.
Nesbitt JC, Jr PJ, Walsh GL, Ryan MB, Roth JA. Malignant diseases of the lung. In: Current Practice of Surgery. Churchill Livingstone, Inc, 1-54, 1995.
Jr PJ, Roth JA. Neoplasms of the esophagus. In: Digestive Tract Surgery: A Text and Atlas. Lippincott-Raven, 43-76, 1995.
Roth JA. The molecular biology of lung cancer. In: Molecular Biology and Molecular Medicine. VCH Publishers, Inc, 518-521, 1995.
Roth JA. Molecular biology and biotechnology. In: Lung Cancer, Molecular Biology of. VCH, 518-521, 1995.
Roth JA, Mukhopadhyay T, Zhang WW, Fujiwara T, Georges R. Gene replacement strategies for the prevention and therapy of cancer. In: The Internet Book of Gene Therapy Cancer Therapeutics. Appleton & Lange, 229-234, 1995.
Roth JA, Putnam JB. Surgery for carcinoma of the esophagus. In: Anonymous Thoracic Oncology. WB Saunders, 397-413, 1995.
Schrump DS, Roth JA. Clinical implications of molecular events in lung cancer. In: Molecular Basis of Oncology. Blackwell Scientific Publications, Inc, 295-316, 1995.
Schrump DS, Roth JA. Molecular biology and immunology of lung and esophageal cancer. In: Glenn’s Thoracic and Cardiovascular Surgery. 6. Appleton & Lange, 331-343, 1995.
Walsh GL, Roth JA. General principles and surgical considerations in the management of mediastinal masses. In: Thoracic Oncology. 2nd. WB. Saunders, 445-467, 1995.
Roth JA. Molecular genetic strategies for the prevention and therapy of lung cancer. In: Lung Cancer: Frontiers in Science and Treatment. Grafica L.P, 83-90, 1994.
Jr PJ, Roth JA. Secondary tumors in the lungs. In: General Thoracic Surgery. Williams & Wilkins, 1334-1352, 1994.
Putnam JB, Roth JA. Surgical resection of pulmonary metastases. In: Cancer Surgery. JB Lippincott Co, 337-350, 1994.
Roth JA. The esophageal mucosa. In: Anonymous O.E.S.O. Elsevier, 1093-1096, 1994.
Roth JA. Is an initial multifocal or diffuse appearance characteristics of adenocarcinoma in CLE?. In: The Esophageal Mucosa. Elsevier, 1093-1996, 1994.
Roth JA, Mukhopadhyay T, Casson AG, Chung KY. Molecular strategies for early detection, prevention and therapy cancer. In: Early Detection of Cancer: Molecular Markers. Armok, Futura Publishing Company, Inc, 45-52, 1994.
Roth JA, Jr PJ. New insights into selecting patients likely to benefit from resection of pulmonary metastases. In: Lung Cancer: Frontiers in Science and Treatment, 473-482, 1994.
Zhang Y, Mukhopadhyay T, Georges R, Roth JA. Molecular targeting of cancer: retroviral vector-mediated antisense nucleic acid therapy. In: Gene Therapy: From Lab to the Clinic. World Scientific Publishing Company, 70-106, 1994.
Mukhopadhyay T, Roth JA. p53 gene mutations in human premalignant and malignant tissues. In: Methods in Molecular Genetics. Academic Press, Inc, 104-128, 1993.
Jr PJ, Roth JA. Neoplastic diseases of the esophagus. In: Digestive Tract Surgery: A Text and Atlas. JB Lippincott, 43-75, 1993.
Putnam JB, Ryan MB, Walsh GL, Roth JA. Malignant disease of the lung. In: Current Practices of Surgery. Churchill Livingstone, Inc, 1-44, 1993.
Roth JA. The biology of lung cancer. In: Thoracic Surgery, 637-647, 1993.
Roth JA. Advances in cell and molecular biology of non-small cell lung cancer. In: Advances in Diagnosis and Therapy of Lung Cancer. Blackwell Scientific, 85-104, 1993.
Roth JA, Jr PJ. Cancer of the esophagus. In: Cancer: Principles & Practice of Oncology. JB Lippincott Co, 776-817, 1993.
Yang SC, Grimm E, Roth JA. Immunotherapy of lung cancer. In: Advances in Diagnosis and Therapy of Lung Cancer. Blackwell Scientific, 379-390, 1993.
Putnam JB, Roth JA. Resection of pulmonary metastases. In: Current Therapy in Oncology. BC Becker, 197-201, 1992.
Roth JA, Sugarbaker PH, Baker AR. Radical forequarter amputation with chest wall resection. In: Anonymous Musculoskeletal Surgery for Cancer. Thieme Medical Publishers, Inc, 317-324, 1992.
Pollock RE, Balch CM, Roth J, McPeek B, Mosteller F. Formulating an initial research plan. In: Principles and Practices of Research: Strategies for Surgical Investigators. Second. Springer-Verlag, 88-90, 1991.
Roth JA. Treatment of metastatic cancer: treatment of metastatic cancer to lung. In: Cancer: Principles and Practice of Oncology. JB Lippincott Co, 2261-2275, 1989.
Roth JA. Solitary pulmonary nodule. In: Common Problems in Gastrointestinal Surgery. Year Book Medical Publishers, 53-58, 1989.
Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Clinical trials with cisplatin, vindesine, and bleomycin neoadjuvant chemotherapy for epidermoid carcinoma of the esophagus. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 253-259, 1989.
Sugarbaker PH, Roth JA. Specialized techniques of cancer management: endoscopy. In: Cancer: Principles and Practice of Oncology. JB Lippincott Co, 423-440, 1989.
Moody FG, Roth JA. The esophagus and diaphragmatic hernias. In: Hardy’s Textbook of Surgery. 2nd. James D. Hardy, 485-513, 1988.
Roth JA. Prognostic indicators for soft tissue sarcoma patients with pulmonary metastases. In: Recent Concepts in Sarcoma Treatment. Kluwer Academic Publishers, 191-196, 1988.
Roth JA. Resection of pulmonary metastases. In: Thoracic Oncology. WB Saunders Co, 619-630, 1988.
Roth JA, Kelsen DP. Surgery and adjuvant chemotherapy for carcinoma of the esophagus. In: Thoracic Oncology. WB Saunders Co, 379-394, 1988.
Ajani JA, McMurtrey MJ, Rich TA, Blackburn R, Chang-Tung E, Levin B, Roth JA, Mountain CF. Carcinoma of the esophagus: Contribution of chemotherapy. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 273-281, 1988.
Kern KA, Pass HI, Roth JA. Surgical treatment of pulmonary metastases. In: Surgical Treatment of Metastatic Cancer. JB Lippincott Co, 69-100, 1987.
Ognibene FP, Pass HI, Roth JA, Shelhamer JH. The diagnosis and therapy of respiratory disease in the immunosuppressed host. In: The Critically Ill Immunosuppressed Patient. Aspen Publications, 39-80, 1987.
Pass HI, Roth JA. Diagnosis of pulmonary metastases. In: Surgical Treatment of Metastatic Cancer. JB Lippincott Co, 36-67, 1987.
Roth JA. Oncogenes and monoclonal antibodies. In: Monoclonal Antibodies for the Diagnosis and Therapy for Cancer. Futura Publishing Co, Inc, 289-321, 1987.
Grimm EA, Roth JA, Yagita M. Effect of OK-432 activated cytolytic lymphocytes on NK resistant fresh tumor cells. In: Host Defense Mechanisms and Immunopotentiators. University of Tokyo Press, 67-74, 1986.
Roth JA. Oncogenes and monoclonal antibodies. In: Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment. Futura Publishing Company, Inc, 1986.
Balch CM, Milton GW, Roth JA. Diagnosis of metastatic melanoma at distant sites. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. JB Lippincott Co, 221-250, 1985.
Rosenberg JC, Roth JA, Lichter AS, Kelsen DP. Cancer of the esophagus. In: Cancer: Principles and Practice of Oncology. JB Lippincott Co, 621-657, 1985.
Roth JA. Treatment of pulmonary metastases. In: Cancer: Principles and Practices of Oncology. JB Lippincott Co, 2117-2131, 1985.
Roth JA. Treatment of metastatic cancer: treatment of metastatic cancer to lung. In: Cancer: Principles and Practice of Oncology. JB Lippincott Co, 2104-2117, 1985.
Roth JA. Endoscopy for thoracic oncologic diseases. In: Cancer: Principles and Practices of Oncology. JB Lippincott Co, 353-406, 1985.
Sugarbaker PH, Roth JA. Specialized techniques of diagnosis: endoscopy. In: Cancer: Principles and Practices of Oncology. JB Lippincott Co, 353-374, 1985.
Roth JA, Sugarbaker PH, Baker AR. Radical forequarter amputation with chest wall resection. In: Atlas of Extremity Sarcoma Surgery. JB Lippincott Co, 177-191, 1984.

Books (edited and written)

Roth JA, Komaki R, Hong WK. Lung Cancer. Ed(s) 4th. Wiley-Blackwell Health Sciences, 2014.
Albelda SM, Andreef M, Aref I, Barton K, Brown S, Chiocca EA, Curiel DT, Dembinski J, Desai A, Ekmekcioglu S, Ellerhorst J, Elshaikh M, Freytag SO, Fueyo J, Fujiwara T, Gerson S, Grimm EA, Haas AR, Hall B, Ji L, Jiang H, Kaur B, Kidd S, Kim JH, Kim K, Klopp A, Lang F, Lin Y, Ling X, Lopez-Berestein G, Lu M, Mangala LS, Marini F, Moon EK, Mora EM, Movsas B, Nemunaitis J, Poindexter N, Pollock RE, Price RL, Ramesh R, Rao DD, Roth JA, Senzer N, Shay JW, Siddiqui F, Singhal S, Sood AK, Spaeth E, Sterman DH, Stricker H, Studeny M, Thacker EE, Torres KE, Vorhies JS, Zeng Z. Gene-Based Therapies for Cancer. Ed(s) 1st. Springer, 2010.
Roth JA, Hong WK, Cox CD. Lung Cancer. Ed(s) 3rd. Blackwell Scientific Publishers, 2007.
Roth JA, Hong WK, Cox CD. Lung Cancer. Ed(s) 2nd. Blackwell Scientific Publishers, Inc, 1998.
Roth JA, Ruckdeschel J, Weisenburger T. Thoracic Oncology. Ed(s) 2nd. WB Saunders Co, 1995.
Mukhopadhyay T, Maxwell SA, Roth JA. p53 Suppressor Gene. RG Landes Co, 1995.
Roth JA, Hong WK, Cox CD. Lung Cancer. Ed(s) 1st. Blackwell Scientific Publishers, Inc, 1993.
Roth JA, Ruckdeschel J, Weisenburger T. Thoracic Oncology. Ed(s) 1st. WB Saunders Co, 1988.
Roth JA. Monoclonal Antibodies for the Diagnosis and Therapy of Cancer. Futura Publishing Company, Inc, 1987.

Patents

Ji LX, Fang B, Roth JA. Novel hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes. Patent Number: 8,658,778.
Roth J, Ji L. Methods and Compositions for TUSC2 Immunotherapy. Patent Number: 2017342364.
Roth JA, Li J. Methods and Compositions for TUSC2 Immunotherapy. Patent Number: ZL 201780076886.X.
Roth JA, Ji L. Methods and compositions for TUSC2 immunotherapy. Patent Number: 11278592.
Roth JA, Ji L. Methods and Compositions for TUSC2 Immunotherapy. Patent Number: 7041136.
|Roth J, Ji L. Methods and Compositions for TUSC2 Immunotherapy. Patent Number: 2755903.
Roth J, Stewart D, Lu C, Wistuba I, Nunez M. FUS1/TUSC2 Therapies. Patent Number: 2,864,394.
Gentile E, Ji L, Roth JA. Cationic Liquid Crystalline Nanoparticles. Patent Number: 3 634 386.
Ji L, Minna JD, Roth J, Lerman M. Chromosome 3p21.3 Genes Are Tumor Suppressors. Patent Number: 9,944,951.
Lin J, Arlinghaus R, Sun T, Ji L, Ozpolat B, Lopez-Berestein G, Roth JA. Bioactive FUS1 peptides and nanoparticle-polypeptide complexes. Patent Number: 8,859,727.
Roth J, Stewart D, Lu C, Wistuba II, Yan S, Nunez MI. TUSC2 Therapies. Patent Number: 9,675,663.
Roth J, Stewart D, Lu C, Wistuba I, Yan S, Nunez MI. TUSC2 Therapies. Patent Number: 2741784.
Ramesh R, Roth JA, Saeki T, Wilson DR. Methods and compositions for non-viral gene therapy for hyperproliferative disease. Patent Number: 60030970.3.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 69535684.4-08.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 1157702.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: AT383167.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 0760675B2.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 2160707.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 69521994.4.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 0760675.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: AT203675.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 222981.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 288790.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 812631.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 43917.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 185749.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: ZL95192776.0.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 325560.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 221279.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 295144.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 284709.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 2146149.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 694216.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: ZL94194354.2.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 698437.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 186151.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 2222600.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 73265.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 275356.
Roth JA, Leman MI, Ji L, Minna JD. Chromosome 3p21.3 genes are tumor suppressors. Patent Number: 7,977,468.
Ramesh R, Roth JA, Saeki T, Wilson DR. Methods and compositions for non-viral gene therapy for hyperproliferative disease. Patent Number: 1180016.
Roth JA, Leman MI, Ji L, Minna JD. Chromosome 3p21.3 genes are tumor suppressors. Patent Number: 2000127337.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 2,174,556.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 5,747,469.
Mukhopadhyay T, Roth JA. 2-methoxyestradiol-induced apoptosis in cancer cells. Patent Number: 5,958,892.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 6,069,134.
Fang B, Roth JA. Diminishing viral gene expression by promoter replacement. Patent Number: 6,110,744.
Zhang WW, Roth JA. Tumor regression by adenovirus expression of wild-type p53. Patent Number: 6,143,290.
Ji L, Roth JA. P16 expression constructs and their application in cancer therapy. Patent Number: 6,251,871.
Zhang WW, Roth JA. Recombinant P53 adenovirus compositions. Patent Number: 6,410,010.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 6,511,847.
Roth JA, Mukhopadhyay T, Tainsky M. Inhibition of cellular proliferation using ras antisense molecules. Patent Number: 6,627,189.
Fang B, Roth JA. Diminishing viral gene expression by promoter replacement. Patent Number: 6,630,344.
Zhang WW, Roth JA. Recombinant P53 adenovirus methods and compositions. Patent Number: 6,740,320.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and P53. Patent Number: 6,797,702.
Zhang WW, Roth JA. Recombinant P53 adenovirus methods and compositions. Patent Number: 6,830,749.
Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 6,905,873.
Roth JA, Mukhopadhyay T, Tainsky MA. Cancer treatment with retroviral vectors comprising wild-type p53. Patent Number: 6,998,117.
Ji L, Roth JA. p16 expression constructs and their application in cancer therapy. Patent Number: 7,163,925.
Roth JA, Cai DW, Mukhopadhyay T. Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A. Patent Number: 6,482,803.
Zhang WW, Roth JA. Methods for the administration of adenovirus p53. Patent Number: 6,805,858.
Wilson DR, Lapadat-Tapolsky M, Timmons TM, Lee JA, Almond BD, Roth JA. Inhibition of cell growth by an anti-proliferative factor. Patent Number: 6,133,416.
Fang B, Roth JA. Diminishing viral gene expression by promoter replacement. Patent Number: 7,244,617.
Zhang WW, Roth J. Adenovirus supervector system. Patent Number: 7,252,989.
Mukhopadhyay T, Chada S, Mhashilkar A, Roth JA. Antihelminthic drugs as a treatment for hyperproliferative diseases. Patent Number: 7,423,015.
Ji L, Minna JD, Roth J, Lerman M. Chromosome 3p21.3 genes are tumor suppressors. Patent Number: 7,902,441.
Zhang WW, Roth JA. Recombinant P53 adenovirus methods and compositions. Patent Number: 7,033,750.
Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 7,109,179.
Lin J, Arlinghaus RB, Sun T, Ji L, Ozpolat B, Lopez-Berestein G, Roth JA. Bioactive FUS1 peptides and nanoparticle-polypeptide complexes. Patent Number: 8,338,366.

Less

CV information above last modified March 27, 2026

Jack A. Roth, M.D., F.A.C.S.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Professional Educational Materials

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Patents

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Jack A. Roth, M.D., F.A.C.S.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Professional Educational Materials

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Patents

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson